

1 **Effect of household use of multiple micronutrient-fortified bouillon on micronutrient status**
2 **among women and children in two districts in the Northern Region of Ghana: Protocol for**
3 **the Condiment Micronutrient Innovation Trial (CoMIT), a community-based randomized**
4 **controlled trial.**

5
6 Reina Engle-Stone^{1,2*}, K Ryan Wessells^{1,2}, Marjorie J. Haskell^{1,2}, Sika M. Kumordzie², Charles
7 D. Arnold², Jennie N. Davis², Emily R. Becher², Ahmed D. Fuseini³, Kania W. Nyaaba³, Xiuping
8 (Jenny) Tan², Katherine P. Adams^{1,2}, Georg Lietz⁴, Stephen A. Vosti^{2,5}, Seth Adu-Afarwuah³

9
10
11 ¹ Department of Nutrition, University of California, Davis, USA

12 ² Institute for Global Nutrition, University of California, Davis, USA

13 ³ Department of Food Science and Nutrition, University of Ghana, Legon, Ghana

14 ⁴ Human Nutrition Research Centre, Institute of Cellular Medicine, Newcastle University,
15 Newcastle upon Tyne, UK

16 ⁵ Department of Agricultural and Resource Economics, University of California, Davis, USA

17
18
19 * Corresponding author

20 E-mail: renglestone@ucdavis.edu (RES)

21 **Pubmed indexing:** Engle-Stone, Wessells, Haskell, Kumordzie, Arnold, Davis, Becher, Fuseini,
22 Nyaaba, Tan, Adams, Lietz, Vosti, Adu-Afarwuah

23 **Short title:** Randomized controlled trial of multiple micronutrient-fortified bouillon in Ghana

24 **Sources of support:** This work was supported, in whole or in part, by a grant from Helen Keller
25 International (66504-UCD-01), through support from the Bill & Melinda Gates Foundation
26 (INV-007916), to the University of California, Davis. Under the grant conditions of the
27 Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to
28 the Author Accepted Manuscript version that might arise from this submission.

29 **Competing interests:** All authors declare no competing interests.

30

31 **Data availability:** Consistent with policy of the Bill & Melinda Gates Foundation, data and forms
32 will be made available online at osf.io/t3zrn/ three years after the completion of data collection.

33

34 **Authors' Contributions:** Conceptualization of the study design: RES, KRW, MJH, SMK, CDA,
35 KPA, SAV, SAA; methods development: all co-authors; manuscript drafting: RES, KRW, MJH,
36 CDA, JND, SAA; manuscript review and editing: all co-authors; supervision and project
37 administration: RES, KRW, MJH, SMK, JND, ERB, ADF, KWN, KPA, SAV, SAA. All authors
38 have read and agreed to the published version of the manuscript.

39

40 **List of Abbreviations**

41 AGP, alpha-1-acid glycoprotein; BIS, Body iron stores; BMI, Body mass index; BP, Blood
42 pressure; CA/TSC, Citric acid/trisodium citrate; CoMIT, Condiment Micronutrient Innovation
43 Trial; CRP, C-reactive protein; CSIRO, Commonwealth Scientific and Industrial Research
44 Organization; DSMB, Data and safety monitoring board; DFE, Dietary folate equivalents; ERC,

45 Ethical review committee; EYT, Early Years Toolbox; FACT, Fortification Assessment
46 Coverage Tool; FDA, Food and Drugs Authority; FGD, Focus group discussion; FFQ, Food
47 frequency questionnaire; FePP, Ferric pyrophosphate; GHS, Ghana Health Service; Hb,
48 Hemoglobin; HCG, Human chorionic gonadotropin; Hct, Hematocrit; HFIAS, Household Food
49 Insecurity Access Scale; HH, Household; HOME, Home Observation Measurement of the
50 Environment; HPLC, High performance liquid chromatography; HWISE, Household Water
51 Insecurity Experiences; ID, Identification; IRB, Institutional Review Board; KAP, Knowledge
52 Attitudes and Practices; MDAT, Malawi Development Assessment Tool; MDD-W, Minimum
53 Dietary Diversity- Women; MUAC, Mid-upper arm circumference; OAA, Opinions, attitudes,
54 and acceptance; PI, Personal identifying information; RAE, Retinol Activity Equivalents; RBC,
55 Red blood cell; RBP, Retinol binding protein 4; RDA, Recommended dietary allowance; RDT,
56 Rapid diagnostic test; RID, Retinol isotope dilution; RISE, Research Institutes of Sweden Ab;
57 SAE, Serious Adverse Event; SAP, Statistical analysis plan; SES, Socioeconomic status; SOP,
58 Standard operating procedure; STEPS, WHO STEPwise Approach to NCD Risk Factor
59 Surveillance; sTfR, Soluble transferrin receptor; WRA, Women of Reproductive Age; UL,
60 Tolerable Upper Intake level; ZPP, Zinc protoporphyrin

61 **ABSTRACT**

62

63 **Introduction:** Micronutrient deficiencies are prevalent in West Africa, particularly among
64 women of reproductive age (WRA) and young children. Bouillon is a promising food
65 fortification vehicle due to its widespread consumption. This study aims to evaluate the impact
66 of multiple micronutrient-fortified bouillon cubes, compared to control bouillon cubes (fortified
67 with iodine only), on micronutrient status and hemoglobin concentrations among lactating and
68 non-lactating WRA and young children in northern Ghana.

69

70 **Methods:** This randomized, controlled doubly-masked trial will be conducted in the Kumbungu
71 and Tolon districts in the Northern Region of Ghana, where prior data indicate multiple
72 micronutrient deficiencies are common. Participants will be: 1) non-pregnant non-lactating WRA
73 (15-49 y), 2) children 2-5 y, and 3) non-pregnant lactating women 4-18 months postpartum.
74 Eligible participants will be randomly assigned to receive household rations of one of two types
75 of bouillon cubes: 1) a multiple micronutrient-fortified bouillon cube containing vitamin A, folic
76 acid, vitamin B12, iron, zinc, and iodine, or 2) a control cube containing iodine only.

77

78 Each participant's household will receive a ration of bouillon cubes every 2 weeks, and
79 households will be advised to prepare meals as usual, using the study-provided cubes. The trial
80 duration will be 9 months for non-pregnant non-lactating WRA and children, and 3 months for
81 lactating women. The primary outcomes will be changes in biomarkers of micronutrient status
82 and hemoglobin. Secondary outcomes will include change in prevalence of micronutrient
83 deficiency and anemia; dietary intake of bouillon and micronutrients; inflammation, malaria, and
84 morbidity symptoms; and child growth and development.

85

86 **Discussion:** Evidence from this study will inform discussions about bouillon fortification in
87 Ghana and West Africa.

88

89 **Trial Registration:** The trial was registered on ClinicalTrials.gov (NCT05178407) and the Pan-
90 African Clinical Trial Registry (PACTR202206868437931). This manuscript reflects protocol
91 version 4 (August 29, 2022).

92

93 **Keywords:** Bouillon, fortification, micronutrients, deficiency, anemia, young children, women,
94 Ghana, West Africa

95

96

97

98

99

100

101

102 **Introduction**

103

104 Micronutrient deficiencies are severe and widespread in West Africa, particularly among young
105 children, pregnant and lactating women, and women of reproductive age [1-3]. These
106 deficiencies have developmental and physical consequences, including increased risk of
107 morbidity and mortality [4], which, in turn, have economic consequences [5]. While various
108 programs to address micronutrient deficiencies have been scaled up, including industrial
109 fortification of cooking oil and wheat flour with micronutrients [6], it is unlikely that a single
110 such program will eliminate all micronutrient deficiencies, since delivery platforms may provide
111 only a subset of nutrients or reach only a subset of the deficient population.

112

113 In Ghana, micronutrient deficiencies remain common, particularly among women and children,
114 despite the presence of various decades-long micronutrient intervention programs [7]. For
115 example, in the 2017 Ghana Micronutrient Survey, the percentage of preschool children who had
116 iron deficiency (serum ferritin <12 µg/L adjusted for inflammation) was 40% for the Northern
117 Belt, 18% for the Middle Belt, and 13% for the Southern Belt [8]. Likewise, the percentage of
118 children with vitamin A deficiency (retinol binding protein <0.70 µmol/L, adjusted for
119 inflammation) was 31%, 18% and 17% for the Northern, Middle, and Southern Belts,
120 respectively. Among non-pregnant WRA (15-49 y), the prevalence of iron deficiency (serum
121 ferritin <15 µg/L, adjusted for inflammation) followed the same pattern as that for pre-school
122 children, with the Northern Belt (22%) being worst off, compared with the Middle (11%) and
123 Southern (14%) Belts. Approximately half of women (50.8% in the Northern belt) had serum
124 folate concentrations < 10 nmol/L [8].

125

126 Wheat flour fortification (iron, zinc, vitamin A, folic acid, and other B vitamins) and cooking oil
127 fortification (vitamin A) are mandatory in Ghana; however, achieving and sustaining high
128 compliance with target fortification levels is a challenge [9]. The 2017 Ghana Micronutrient
129 Survey found that only 56% of oil samples (36% in the Northern Belt) were adequately fortified
130 with vitamin A (≥ 10 mg/kg vitamin A), and only 6% of wheat flour samples (6% in the Northern
131 Belt) had adequate iron concentrations (≥ 58.5 mg/kg as mandated by Ghana's food fortification
132 standards) [10]. Similar challenges with implementation of fortification programs have been
133 observed elsewhere in the region [11]. Further efforts are thus required to address the high
134 prevalence of micronutrient deficiencies in Ghana and elsewhere in West Africa.

135
136 Bouillon cubes are widely consumed in West Africa and therefore hold great potential for
137 addressing micronutrient deficiencies in the region [12-14]. Bouillon is particularly attractive as
138 a food vehicle because consumption is high even among subsets of the population typically at
139 risk for micronutrient deficiencies, such as those residing in rural areas and households with low
140 socioeconomic status [12, 15]. Estimates of the proportion of households consuming bouillon in
141 the past week have ranged from 79% to 99% in Burkina Faso, Cameroon, Niger, and Senegal
142 [16]. In Ghana, preliminary analyses of household data [17] suggested that 72% of households
143 had acquired bouillon products in the prior 18 days.

144
145 In West Africa, some brands of bouillon have been produced with iodized salt since the 1990s,
146 and bouillon products fortified with iron or vitamin A, in addition to iodine, have been
147 introduced by some companies on a voluntary basis [18]. A study in Senegal found that iodine
148 fortification of bouillon could potentially contribute substantially to iodine intake, by providing
149 between 7%-115% of the recommended daily intake, depending on the iodine content of the
150 cubes [19]. In northern Ghana, a study of schoolchildren 6-13 years of age [20] found that

151 around two-thirds (2/3) of dietary iodine was obtained from iodine-fortified bouillon cubes.
152 Other modelling studies have found that bouillon cube fortified with vitamin A could reduce the
153 prevalence of inadequate vitamin A intakes without leading to an increase in excessive intakes
154 among women or children in Cameroon [21], and would complement other intervention
155 programs in reducing inadequate intake of vitamin A [22].

156
157 The foregoing evidence suggests that the fortification of bouillon, in combination with other
158 ongoing measures, could contribute to the prevention of micronutrient deficiencies in Ghana.
159 However, the levels of micronutrients that are currently included in commercial bouillon
160 products on a voluntary basis (e.g., iron) may not be sufficient to meet public health needs [23].
161 Moreover, no commercial bouillon products have been released that address deficiencies in other
162 key nutrients, such as zinc, folate, and vitamin B-12. Therefore, research is needed to explore the
163 efficacy of fortified bouillon for addressing micronutrient deficiencies. To our knowledge, no
164 studies, in West Africa or elsewhere, have tested the impact of multiple micronutrient-fortified
165 bouillon on micronutrient status.

166

167 [Study objectives](#)

168 The primary objectives are to assess the effects of household use of multiple
169 micronutrient-fortified bouillon cubes (containing iodine in addition to vitamin A, folic
170 acid, vitamin B12, iron, and zinc), compared to control bouillon cubes (fortified with
171 iodine only), on micronutrient status and hemoglobin concentrations among non-
172 pregnant, non-lactating women 15-49 years of age (referred to hereafter as women of
173 reproductive age, WRA) and among children 2-5 years of age, and breast milk
174 micronutrient concentrations among non-pregnant, lactating women 15-49 years of age at
175 4-18 months postpartum (hereafter, lactating women).

176
177 Secondary objectives include the effect of the multiple micronutrient-fortified bouillon,
178 compared to the control bouillon, on the prevalence of micronutrient deficiencies and anemia;
179 dietary intake of bouillon and micronutrients; inflammation, malaria, and morbidity symptoms;
180 and children’s anthropometric measures and child development (details of primary and
181 secondary outcomes for each physiological group are listed in supplemental material **S1 and S2**).
182 Sub-studies will also assess opinions, attitudes, and acceptance (OAA) of the multiple
183 micronutrient-fortified bouillon and hypothetical willingness-to-pay (WTP) for multiple
184 micronutrient-fortified bouillon.

185
186 We generally hypothesize that micronutrient status, hemoglobin concentrations, dietary nutrient
187 intake, child growth, and child development scores will be greater, and that prevalence of each
188 micronutrient deficiency, anemia, and inflammation and morbidity will be lower, among
189 participants who receive the multiple micronutrient-fortified bouillon compared to those who
190 receive the control bouillon. Specific hypotheses will be reported in statistical analysis plans that
191 will be posted prior to data analysis.

192

193

194 **Materials and Methods**

195

196 The trial was registered on ClinicalTrials.gov (NCT05178407) and the Pan-African Clinical Trial
197 Registry (PACTR202206868437931). The full study protocol and statistical analysis plans are
198 posted on Open Science Framework (<https://osf.io/t3zrn/>).

199

200 Study design

201 This community-based trial will follow a randomized, controlled doubly-masked design. WRA
202 (n=1028), children (n=690), and lactating women (n=690) will be recruited from households in
203 selected communities within the Kumbungu and Tolon districts, Northern Region, Ghana. The
204 flow of study activities for each of the 3 physiological groups, and summary of exclusion and
205 deferral criteria, are illustrated in **Figure 1**, while the schedule of data collection is summarized
206 in **Table 1**. Written informed consent will be obtained from participating women and from
207 caregivers of participating children. Consented WRA will be invited for a screening visit for
208 assessment of total body vitamin A stores using the retinol isotope dilution (RID) technique [24].
209 Following a 3-week observation period, which includes 2 in-home visits, all participants will
210 undergo baseline assessment, and eligible participants will be enrolled by being randomly
211 assigned to receive household rations of one of two types of bouillon cubes: 1) a multiple
212 micronutrient-fortified bouillon cube containing vitamin A, folic acid, vitamin B12, iron, zinc,
213 and iodine, or 2) a control cube fortified only with iodine. Households will be advised to prepare
214 their meals as usual, but will be requested to use the study-provided bouillon instead of the
215 commercially available bouillon they typically purchase. Households will then be visited every 2
216 weeks for delivery of study cubes, monitoring of adherence, and recording of morbidity
217 symptoms. Endline assessments will be conducted after ~9 months (35 and 38 weeks) for WRA
218 and children, and after ~3 months (11 and 12 weeks) for lactating women. Details of study
219 procedures and data collection at each time point are summarized in **Table 1** and below.

220

221 **Figure 1. Flow of study activities.**

222

Table 1. Schedule of recruitment, screening, enrolment, intervention, and assessments.

Type of data collection	Recruitment	Screening (WRA)	Observation period	Baseline	Intervention Period					Study check-out
					Initial	Biweekly	4-weekly	Endline 1	Endline 2	
ENROLLMENT										
	Household eligibility	x								
	Individual eligibility	x	x		x					
	Informed consent	x								
	Retinol isotope dosing (WRA)		x						x	
	Enrollment				x					
	Study group allocation				x					
INTERVENTION										
	Bouillon provision					←—————→				
	Adherence monitoring						x			x
ASSESSMENTS										
Household data collection										
	Demographics, SES	x								
	Household bouillon KAP	x		x		x	x			x
	FACT	x				x		x		
	Willingness to pay	x								x
	Opinions, attitudes, acceptance ¹			x		x (+ 60 d)				x (-60 d)
	Food and water security	x				x		x		
Index participant data collection										
Anthropometry										
	MUAC	x			x				x	
	Length, weight, waist and hip circumference				x				x	
Morbidity										
	Health history			x		x				
	Blood pressure		x		x				x	x
	Morbidity surveillance	x	x	x		x	x			x
Blood sample collection										
	Hemoglobin		x		x				x	x

	Hematocrit				x				x	x	
	Infection indicators (malaria, CRP, AGP)		x		x				x	x	
	Vitamin A isotopes (WRA)				x					x	
	Micronutrient status indicators (plasma ferritin, sTfR, zinc, RBP, retinol, B12; whole blood folate, plasma/serum folate, ZPP)				x				x	x	
Urine sample collection											
	HCG (WRA)		x						x		
	Iodine, sodium		x		x				x		
Breast milk sample collection											
	Micronutrient status indicators (vitamin A, B12)				x				x	x	
Stool sample collection											
	Inflammation indicators (calprotectin)				x				x		
	Microbiome				x				x		
Dietary											
	Food frequency questionnaire					x		x			
	24 h recalls			x		x (+ 30 d)					x (-30 d)
Child development											
	Home inventory			x							x (-21 d)
	MDAT			x							x (-21 d)
	YET			x							x (-21 d)

225 ¹ In addition, one round of focus group discussions will be conducted during the intervention period among a subset of participants in the OAA substudy. AGP, alpha-1-acid glycoprotein; CRP, C-reactive protein;
226 EYT, Early Years Toolbox; FACT, Fortification Assessment Coverage Tool; HCG, human chorionic gonadotropin; KAP, knowledge attitudes and practices; MDAT, Malawi Developmental Assessment Tool;
227 MUAC, mid-upper arm circumference; RBP, retinol-binding protein; SES, socioeconomic status; WRA, women of reproductive age; ZPP, zinc protoporphyrin.

228

229 Study site

230 This proposed research will take place in the Tolon and Kumbungu districts in the Northern
231 Region. Micronutrient biomarker data from a pilot survey in these districts (not yet published)
232 confirmed prior research [10] that suggests micronutrient deficiencies are common. For example,
233 pilot data indicated that 28% of WRA and 53% of children 2-5 years of age were iron deficient
234 (serum ferritin concentration <15 or <12 $\mu\text{g/L}$, respectively, adjusted for inflammation). In
235 addition, 34% of children had evidence of vitamin A deficiency (serum retinol <0.70 $\mu\text{mol/L}$,
236 adjusted for inflammation) although only $\sim 1\%$ of WRA had serum retinol <0.70 $\mu\text{mol/L}$. Serum
237 vitamin B12 concentrations were low (<221 pmol/L) among 12% of women and 19% of children
238 2-5 y, while low vitamin B12 concentrations in breast milk (<221 pmol/L) were observed among
239 40% of lactating women. Anemia was also common among both women (31%) and children 2-5
240 years of age (36%). Consumption of micronutrient supplements of any type was rare, with fewer
241 than 10% of WRA and children interviewed in the pilot survey reporting consumption in the
242 previous 30 days. Similarly, pilot survey data also confirmed inadequate compliance with
243 mandatory target micronutrient fortification levels of industrially fortified foods. Data on
244 micronutrient levels in food samples collected at the study site indicate that oil samples were
245 fortified with amounts equivalent to $\sim 69\%$ of target vitamin A levels and wheat flour samples
246 were fortified with $\sim 33\text{-}34\%$ of target levels for iron and zinc (not yet published).

247

248 Identification and recruitment of participants

249 Participants in the study will be 1) non-pregnant non-lactating WRA 15-49 years of age,
250 2) children 2-5 years of age, and 3) non-pregnant, lactating women 15-49 years of age at
251 4-18 months postpartum. Multiple participants may be recruited from the same household
252 if they represent different physiological groups (for example, a WRA and child 2-5 years
253 of age), but only one index participant (e.g., one WRA) from each physiological group

254 will be recruited from each household. A household is defined as a group of people who
255 recognize the same head of household, live together, and share living expenses and meals
256 (see **S5. Supplemental Methods** for full definition). Sub-study respondents will be 1)
257 OAA: an adult household member (≥ 15 years of age) who is not recruited in the trial,
258 and 2) WTP: the household member who is primarily responsible for making decisions
259 about bouillon purchasing.

260
261 Within the Tolon and Kumbungu districts, we will recruit potential participants from 16
262 recruitment sites composed of 14 “rural” (comprising both rural and semi-urban areas) and 14
263 urban Ghana Statistical Service designated sampling areas. Recruitment of each physiological
264 group (WRA, children, lactating women) will be balanced within each recruitment site so that
265 the final sample of participants in each physiological group represents a similar geographic area.
266
267 Households in selected recruitment sites will be identified through a random walk method with
268 door-to-door recruitment[25]. Trained enumerators fluent in English and the local language
269 (Dagbani) will approach households to assess eligibility, administer recruitment questionnaires,
270 and conduct the informed consent process.

271

272 **Consent**

273 Upon selecting a household to approach, enumerators will first obtain oral consent from the head
274 of household to proceed with the interview and then will administer a series of questionnaires to
275 assess interest in study participation and complete a household roster. The household roster will
276 be used to identify potentially eligible individuals. If more than one potentially eligible
277 individual per physiological group is present in the home (for example, if there are two children
278 between 2-5 years of age), one individual per physiological group will be randomly selected

279 based on a Kish Table [26]. Potentially eligible participants will then complete the written
280 informed consent process, wherein enumerators read aloud the consent form in the preferred
281 language of the participant (English or Dagbani), concluding with an informed consent quiz to
282 confirm the participant's understanding of the study procedures. Informed consent will be
283 confirmed with a signature or thumbprint; impartial witnesses (community members not
284 affiliated with the study) fluent in English and Dagbani will be present for the consent process
285 for non-literate participants to ensure the information presented orally matches the written
286 informed consent sheet. Caregivers will provide consent for children 2-5 years; participants 15-
287 17 years who have never married and are living with their parents will provide assent and their
288 caregiver will provide consent. After an index participant has consented to participate in the
289 study, respondents for the OAA and WTP sub-studies will be recruited. For the OAA sub-study,
290 enumerators will use the household's roster and a random number generator to randomly select
291 the OAA participant from all remaining adult household members (e.g., ≥ 15 years and not
292 recruited into the RCT); one OAA participant will be recruited per household. Upon agreement
293 to participate in the OAA sub-study, the selected adult household member will provide written
294 informed consent. For WTP, the household member with primary responsibility for bouillon
295 purchasing (who may or may not be a participant in the RCT) will be asked to provide oral
296 consent to respond to questions to elicit their hypothetical willingness to pay for a fortified
297 bouillon cube.

298

299 [Inclusion and Exclusion Criteria, and Deferral Criteria](#)

300 Detailed descriptions of the research inclusion and exclusion criteria by physiological group and
301 at each stage of the study are included in **S5. Supplemental Methods** and summarized in **Figure**
302 **1**. Briefly, households will be eligible for recruitment if the household is willing to use the study-
303 provided bouillon cubes for the duration of the study and no one in the household i) is currently

304 participating in another research trial, ii) has a chronic medical condition requiring frequent
305 blood transfusions, or iii) has an allergy to ingredients in the bouillon cubes (shrimp, wheat,
306 milk, soy, eggs, celery, fish, or mollusc). WRA, lactating women, and children will be eligible
307 for inclusion if they i) do not have a severe acute or chronic illness, ii) are able to provide
308 informed consent, and iii) plan to remain in the study area for the duration of the study.
309 WRA must have a negative malaria rapid diagnostic test (RDT) result and C-reactive protein
310 (CRP) <5 mg/L at the RID screening visit, and hemoglobin (Hb) \geq 8 g/dL at the screening and
311 baseline visits. Children must have mid-upper arm circumference (MUAC) of \geq 11.5 cm at
312 recruitment, and Hb \geq 7 g/dL, weight-for-height z-score (WHZ) \geq -3 SD, and no bilateral pitting
313 oedema at baseline.

314

315 Throughout the study, WRA and lactating women who report pregnancy, and lactating women
316 who report lactation cessation, will be excluded. Participants who present with COVID-19-
317 related symptoms, or malaria or elevated CRP (WRA screening visit only), will be required to
318 defer study assessments for 2-3 weeks (**Figure 1; Supplemental Methods**). At the RID
319 screening or baseline visits, if participants do not meet inclusion criteria after the deferral period,
320 they will be excluded.

321

322 The following sections describe the sequence of study visits and procedures.

323

324 [Screening and baseline visits](#)

325 Following recruitment and consent, WRA will visit the study site to be screened for eligibility
326 for the RID test for assessment of total body stores of vitamin A [24]. Then, during a 3-wk
327 observation period, descriptive information will be collected for all participants at two in-home
328 visits. Following the 3-wk observation period, all participants will visit the study site for baseline

329 assessments; eligible participants will be randomized to a treatment group. Procedures at each
330 visit are summarized below.

331
332 **RID screening visit for non-pregnant, non-lactating women of reproductive age**
333 WRA will be screened for eligibility for the RID test using procedures described below.
334 Fieldworkers will assess participants for recent morbidity, vitamin A intake (e.g., liver or
335 supplements in the past 24h) and pregnancy (based on human chorionic gonadotropin in urine),
336 measure blood pressure and collect a capillary blood sample. WRA with no recent (past 72h)
337 morbidity or intake of vitamin A-rich foods (e.g., liver) in the past 24h, who have a negative
338 pregnancy test, Hb ≥ 8 g/dL, CRP < 5 mg/L, and a negative malaria RDT result will receive an
339 oral dose of d6-labelled vitamin A (2 mg retinol equivalent, sourced from Buchem BV,
340 Apeldorn, Netherlands) in sunflower oil. The labelled vitamin A will be certified as food grade
341 (Food Chemical Codex IV) and approved by the Ghana Food and Drugs Authority. All WRA
342 who received the d6-labelled vitamin A dose will be invited to the biospecimen collection site 21
343 days after the isotope dose (based on Green et al., 2021 [27]) for a venous blood sample to assess
344 total body vitamin A stores using the RID technique. This 21-day visit will be scheduled to
345 coincide with the trial baseline visit (procedures described below).

346
347 **Observation period**

348 For all participants, during the ~3-week period between recruitment and the baseline visit (i.e.,
349 the observation period), information on participant and household characteristics, dietary intake,
350 morbidity, and bouillon use will be collected during two household visits conducted 2 weeks
351 apart. Baseline child development assessments will also occur during this period. Additionally,
352 OAA participants will complete a demographic questionnaire and one quantitative survey about
353 opinions, attitude, and acceptance of commercial bouillon.

354

355 [Baseline visit](#)

356 After completion of the observation period, eligible participants will be invited to the mobile
357 biospecimen collection site for the baseline visit (**Figure 1; Table 1**). Following morbidity
358 screening, participants will undergo baseline data collection procedures, including
359 anthropometry, measurement of blood pressure and collection of a spot urine sample (WRA and
360 children only), and collection of a stool sample (children only). Venous blood will be collected
361 from WRA (fasted) and children (nonfasted) for assessment of hemoglobin, malaria, and
362 biomarkers of micronutrient status and inflammation. For lactating women, a full breast milk
363 sample will be collected for micronutrient analysis. Questionnaires will be used to collect
364 individual level information related to the interpretation of biospecimen results.

365

366 Following the baseline data collection procedures, households with participants who remain
367 eligible for the study will be randomized to a study arm; an enumerator will visit the household
368 on the following day (the initial home visit) to deliver the first ration of bouillon cubes that
369 corresponds to the assigned treatment group.

370

371 [Randomization and blinding](#)

372 The unit of randomization will be at the household level, regardless of the number of individual
373 participants (up to 3) eligible within that household. To randomize the households, the trial
374 statistician will create a computer-generated block randomization scheme with randomly selected
375 block lengths of four or eight. Pieces of paper bearing intervention group assignments
376 represented by 4 different 3-digit alphanumeric codes (2 codes per study arm) and numbered 1–
377 2408 (maximum number of households if each participant resides in a different household) will
378 be placed in opaque envelopes and stacked in increasing order by study staff not involved in the

379 randomization process. For each household enrollment, a designated and trained study personnel
380 will select the four topmost envelopes from the stack and ask the participant to choose an
381 envelope to reveal their study group assignment. At this point, the household ID (and the
382 participant IDs for each eligible participant within the randomized household) will be linked to
383 one of the four study codes indicating the intervention the household will receive.

384

385 All study bouillon cubes will be individually wrapped in identical packaging and will be
386 identified only by the study code (a 3-digit alphanumeric code). Boxes of cubes will be labelled
387 with the study code and an associated group color. Participants and study personnel will know
388 the code (and for study personnel, the group color) to which each household is assigned but will
389 not know the micronutrient content of the products.

390

391 Two code keepers (one at the University of California, Davis, UCD, and one at the University of
392 Ghana) who are not otherwise affiliated with the study will be responsible for assigning the 4
393 study codes to the intervention products and communicating directly with the manufacturer about
394 the group assignments. In addition, a hard copy of the randomization code will be stored in a
395 sealed envelope in a locked filing cabinet at the University of Ghana. Two individuals,
396 unaffiliated with the study, will have a key to the office and access to the key to the filing
397 cabinet. In the case of a severe adverse reaction pertaining to an individual participant, the
398 blinding code will be broken only to identify the bouillon cube formulation that the individual
399 participant received, if necessary for their medical care. Only individuals directly involved in the
400 care of the study participant will be unblinded on a strict need-to-know basis.

401

402 The specific bouillon cube formulation associated with each of the 4 study codes will also be
403 stored in sealed envelopes held by the co-principal investigators and the statistician. The

404 envelopes will be opened only after statistical analyses of the primary outcomes are completed
405 and the investigators have reached consensus on interpretation of the results.

406

407 [Intervention period procedures](#)

408 Enumerators will visit participant households every 2 weeks throughout the study to provide the
409 study bouillon rations and collect information on adherence (e.g., household inventory of study
410 bouillon and commercial bouillon, bouillon wrapper counts, bouillon use) and morbidity. All
411 reasonable efforts will be made to complete follow-up assessments, regardless of adherence.
412 Questionnaires to collect information on household food insecurity, water insecurity,
413 consumption of fortified foods, and dietary patterns (e.g., dietary diversity and child feeding)
414 will also be administered during the initial home visit and every 4 weeks thereafter (Table 1).
415 Cube delivery and data collection will be conducted with “no contact” methods (e.g., phone
416 interview) in the case of COVID-19 exposure or symptoms. Baseline dietary assessment will be
417 conducted by administering two 24-hour dietary recall interviews per participant on non-
418 consecutive days within 30 days after the baseline visit (all participants), and two additional 24-
419 hour dietary recalls will be conducted on non-consecutive days within the 30 days before the
420 second endline visit (WRA and children only).

421

422 Within the first two months of the intervention period, OAA participants will complete a similar
423 quantitative survey to that administered in the observation period but focused on the study-
424 supplied bouillon cubes, and again within the last two months of the intervention period. OAA
425 participants in households in which the only trial participant is a lactating woman will complete
426 only one intervention period survey.

427

428 Endline visits

429 At the end of the intervention period, participants will be invited to the mobile biospecimen
430 collection site for the two endline data collection visits (35 weeks and 38 weeks for WRA and
431 children; 11 weeks and 12 weeks for lactating women). A 3-week period between endline visits
432 was chosen based on the desired timing between the isotope dose administration and blood
433 collection for assessment of total body vitamin A stores. Delivery of study bouillon cubes will
434 continue through the last endline assessment for each household. Data collection procedures at
435 the first endline visit will be similar to those described at the baseline visit. Briefly, data
436 collection will include anthropometric measurements and morbidity symptoms (all participants);
437 spot urine samples, blood pressure measurement and venous blood collection (WRA and
438 children); breast milk collection (lactating women); and stool collection (children).

439

440 In addition, at the first endline visit (35 wk), WRA will receive an oral dose of $^{13}\text{C}_{10}$ -retinyl
441 acetate (2 mg retinol equivalents, sourced from Buchem BV, Apeldorn, Netherlands) to assess
442 total body vitamin A stores. $^{13}\text{C}_{10}$ -retinyl acetate will be used at endline to avoid any potential
443 interference from the baseline dose of d6-retinyl acetate. To assess eligibility for the endline
444 isotope dose, participants will undergo screening procedures identical to those at the pre-
445 intervention screening visit, including assessment of morbidity symptoms, vitamin A intake,
446 pregnancy (based on measurement of HCG in urine), anemia, malaria infection, and
447 inflammation. Based on results of these assessments, WRA will either be 1) eligible to receive
448 the endline isotope dose and continue with the study; 2), deferred and scheduled to be re-
449 screened for isotope dosing at the 2nd endline visit (recent morbidity, CRP > 5 g/L, positive
450 malaria RDT); 3) excluded from isotope dosing and the second endline blood collection
451 (participants with Hb < 8 g/dL), or 4) excluded from the study (positive pregnancy test) (see **S5.**
452 **Supplemental Methods** for detailed exclusion and deferral criteria).

453
454 Data collection procedures at the second endline assessment will include a subset of the
455 outcomes measured at the first endline assessment, measured using identical methods. These will
456 include morbidity symptoms (all groups), venous blood collection (WRA and children) and
457 breast milk collection (lactating women). WRA who are deferred at the first endline visit, and do
458 not receive the vitamin A isotope dose, will be re-screened at the second endline visit using the
459 same procedures for eligibility described above. WRA who are eligible to receive the isotope
460 dose at the second endline will be asked to return for an additional endline visit to collect a
461 follow-up venous blood sample for RID assessment 3 weeks later.

462
463 In between the two endline visits (35wk and 38wk), a single endline child development
464 assessment will be completed for each task. After the second endline visit, a final home visit will
465 be conducted to complete the study exit form and collect all remaining study bouillon cubes from
466 the household. In each household, the baseline assessment of hypothetical willingness-to-pay for
467 a fortified bouillon cube will be repeated at endline.

468

469 [Intervention: Fortified bouillon development](#)

470 [Product formulation](#)

471 Bouillon cubes for the trial will be produced based on a non-proprietary formulation that is
472 comparable to commercial cubes sold in Ghana, containing ~52% salt by weight, along with
473 palm fat, corn starch, spices and flavour enhancers, colouring, and micronutrient premix
474 (Nicholas Archer, CSIRO, personal communication). Shrimp flavour was selected, as it was the
475 primary bouillon flavour used by all households in the pilot survey in the study community [28].
476 **Table 2** presents the micronutrient concentrations, chemical fortificant forms of each nutrient,
477 and equivalent daily target micronutrient doses for women and young children in the active arm

478 of the study. The specific fortificants were selected on the basis of technical compatibility with
479 the food matrix and experience with use as fortificants [29]. In the case of iron, the combination
480 of ferric pyrophosphate (FePP) with a citric acid/trisodium citrate buffer (CA/TSC) is expected
481 to enhance bioavailability compared to FePP alone [30].

482
483 With estimated typical bouillon consumption of 2-2.5 g/d among WRA and 1 g/d among
484 children, these cubes supply a daily dose of micronutrients equivalent to 33% to 133% of the
485 corresponding US Recommended Daily Allowance for the 6 micronutrients added to the cubes
486 (**Table 2**). The concentrations of micronutrients were selected based on: 1) modelling of national
487 survey data from Ghana and other West African countries to estimate the contribution of
488 hypothetical fortification of bouillon to adequacy of dietary micronutrient intake (to estimate the
489 potential public health benefit) [14]; 2) the estimated amount of bouillon consumed in the
490 communities selected for the study; 3) expected efficacy, based on a literature review of the
491 effect of micronutrient interventions on change in micronutrient status as measured by
492 biomarkers or on clinical outcomes (anemia and neural tube defects) and estimated accumulation
493 of micronutrient stores (vitamin A and iron); and 4) safety considerations, including the
494 likelihood of study participants or their household members exceeding the tolerable upper intake
495 level (UL), and a review of the literature to identify adverse effects of micronutrient
496 interventions at varying daily micronutrient doses. Additional details on the rationale for the
497 selected fortification levels and estimated daily micronutrient doses are provided as a Technical
498 Appendix to the study protocol (available at <https://osf.io/t3zrn/>).

499
500 The control cube formulation contains iodine but no other added micronutrients. This selection
501 of micronutrient for the control cube is consistent with current policy in Ghana, where salt

502 iodization is mandated (15 mg/kg at household level) [31] and commercial bouillon cubes are
503 typically made with iodized salt [18].

504

505 [Product testing](#)

506 Acceptability of the unfortified, non-proprietary cube formulation was confirmed through
507 consumer testing in northern Ghana, including using commercial cubes as a reference (Nicholas
508 Archer, CSIRO, personal communication). The effects of micronutrient fortification on
509 micronutrient stability and sensory properties of the multiple micronutrient-fortified bouillon
510 were evaluated in accelerated storage trials. The results confirmed good stability and cube
511 quality after 2 weeks of storage of bouillon cubes (in individual wrappers) under accelerated
512 storage conditions (37°C, 75% relative humidity), and for at least 5 months for storage under
513 optimal conditions (23°C, 50% relative humidity) (Nicholas Archer, CSIRO, personal
514 communication). Finally, acceptability of the multiply-fortified and control cube formulations
515 used in this study was evaluated among a sample of women and their households in the study
516 community [32]; overall, the study results suggested that the bouillon formulations were well
517 liked and would be suitable for use in further research studies.

518

519 [Bouillon cube production and management](#)

520 Bouillon cubes will be produced at industrial scale by GB Foods (Barcelona, Spain). Bouillon
521 cubes will be shipped by air or sea to Ghana and transported to a dedicated storage facility at the
522 study site. Boxes of bouillon will be stored on pallets in a cool (12 – 16° C) temperature-
523 controlled environment with frequent temperature and humidity monitoring. Micronutrient
524 content of the micronutrient premix and the study bouillon cubes will be analyzed to ensure
525 proper coding and formulation of the bouillon cubes before distribution to participants.

526

527 **Table 2. Target fortification levels, estimated daily dose of micronutrients delivered by**
 528 **fortified bouillon, and percent of the recommended daily allowance for women of**
 529 **reproductive age and young children¹**
 530

Micronutrient (Fortificant)	Amount of micronutrient per gram bouillon²	Daily amount provided to women³	Daily amount provided to women, as proportion of the RDA	Daily amount provided to children	Daily amount provided to children as proportion of the RDA
Vitamin A (retinyl palmitate)	200 µg	400 - 500 µg	57 - 71%	200 µg	50 - 67%
Folic acid	80 µg	160 - 200 µg	67 - 83%	80 µg	67 - 89%
Vitamin B12	1.2 µg	2.4 - 3.0 µg	100 - 125%	1.2 µg	100 - 133%
Iron (FePP/CA/TSC)	4 mg	8 - 10 mg	44 - 56%	4 mg	40 - 57%
Zinc (ZnO)	3 mg	6 - 7.5 mg	75 - 94%	3 mg	60 - 100%
Iodine (KIO ₃)	30 µg	60 - 75 µg	40 - 50%	30 µg	33%

531 ¹Recommended Daily Allowance (RDA) values are for women 19-50 years of age and children
 532 1-3 y and 4-8 y [33]. FePP/CA/TSC: ferric pyrophosphate/citric acid/trisodium citrate. Values do
 533 not include overage. Overages based on expert opinion were added to account for losses during
 534 storage and cooking (30% vitamin A, folic acid, and vitamin B12; 20% iodine; 0% iron and
 535 zinc).

536 ²Values represent the amount of the active form of the nutrient, e.g. 200 µg retinol equivalents as
 537 retinyl palmitate and 4 mg iron as FePP/CA/TSC.

538 ³Range of values reflects assumed bouillon cube intake of 2-2.5 grams per day among WRA. For
 539 children, calculations assume 1 gram per day and RDA categories of 1-3 years and 4-8 years of
 540 age (representing children 2-5 years of age).

541
 542 **Household bouillon ration**

543 The household bouillon ration will be determined based on household size and estimated
 544 bouillon consumption (2.5 g/capita/d). This approach was based on previous research in the
 545 study community showing that median per household bouillon consumption was 20 (12, 24) g/d
 546 (median, p25, p75) and that bouillon consumption was 2.4 g/d among WRA and 1.0 g/d among
 547 children, similar to the assumptions in Table 2 [28]. The household bouillon ration may be
 548 revised over the course of the study based on observations and questionnaire responses (e.g.,
 549 changes to household composition) but will not exceed 4 g/capita/d. Bouillon rations will be
 550 delivered by enumerators to participants' homes every 2 weeks and stored in study-provided

551 plastic containers. Households will be encouraged to use the study bouillon (in lieu of
552 commercially purchased bouillon cubes) according to their typical cooking habits. At the initial
553 home visit (first day of bouillon distribution) only, the enumerator will request to collect all
554 commercial bouillon in the household; if the household agrees, they will be compensated
555 according to a table of current brand-specific market prices for bouillon. During the trial,
556 households are free to purchase and use commercial bouillon cubes as they choose.

557

558 [Data collection methods](#)

559 [Questionnaires](#)

560 Trained enumerators will administer all questionnaires in the preferred language of the
561 participant (English or Dagbani) as structured oral interviews using electronic tablets. Data on
562 demographic and socio-economic status (household size and composition, assets, housing
563 quality, sanitation and hygiene, and individuals' education and occupations), food security
564 [Household Food Insecurity Access Scale (HFIAS) [34]] and water security [Household Water
565 Insecurity Experiences (HWISE) [35]] will be collected. Pilot-tested questionnaires will also
566 collect information on household bouillon acquisition, consumption, and stocks; bouillon
567 knowledge, attitudes and practices (KAP); consumption of fortified foods, including bouillon
568 [Fortification Assessment Coverage Tool (FACT)[26]; and hypothetical willingness-to-pay
569 (WTP) for a new micronutrient-fortified bouillon cube. Information on health history, non-
570 communicable disease risk [WHO STEPwise approach to NCD risk factors surveillance
571 (STEPS) questionnaire] [36], and breastfeeding and infant and young child feeding practices
572 (IYCF) [37] and dietary diversity (Dietary Quality Questionnaire [DQQ]) [38] will also be
573 collected. Parent perception of child weight and parental beliefs, attitudes and practices toward
574 child feeding will be assessed with a child feeding questionnaire (CFQ) [39]. Structured

575 questionnaires will be used to assess recent morbidity (presence and severity of selected
576 symptoms of pre-defined diseases and serious adverse events).

577

578 [Adherence](#)

579 Households will be requested to save wrappers from all bouillon (both study-provided and
580 commercial) used in the household since the last biweekly visit. To monitor adherence, at each
581 biweekly visit during the intervention period, enumerators will count the bouillon wrappers and
582 record an inventory of all bouillon cubes in the household (both study-provided and
583 commercial). In addition, enumerators will administer a questionnaire to gather data about
584 household purchases of bouillon and household bouillon use in the past 2 weeks, including
585 sharing of study bouillon cubes with non-household members. Households with sustained low
586 adherence (i.e., low consumption of study-provided bouillon) will be identified through routine
587 adherence data monitoring; enumerators will be instructed to inquire about the reasons for low
588 adherence and to encourage use of the study bouillon.

589

590 [24 hour recalls](#)

591 Quantitative dietary intake data will be collected through 24-hour dietary recall interviews to
592 capture bouillon and nutrient intake both prior to and while receiving the study cubes. All
593 participants (WRA, lactating women, children) will complete one dietary recall during the
594 observation period and two baseline dietary recalls on non-consecutive days within the first 30
595 days of the intervention period. WRA and children will complete two additional endline recalls
596 on non-consecutive days within the 30 days before the second endline visit. Lactating women
597 will not complete endline dietary recalls due to the shorter study duration.

598

599 Dietary recalls will be conducted by enumerators with extensive training and practice on the 24-
600 hour recall technique. Interviews will follow a multiple pass methodology [40] to collect
601 information on all foods and beverages consumed by each participant during a defined 24 hour
602 period. Recall data will be collected using a tablet-based data collection system (an adaptation of
603 OpenDRS [41]) that allows for direct entry of dietary data and recipe collection on the tablet,
604 through a platform that guides interviewers through the dietary recall interview and suggests
605 prompts to aid in the interview process. Dietary recalls will be conducted in participant
606 households to take advantage of the opportunity to use the participants' typical utensils for
607 portion size estimation where possible. Enumerators will also carry "kits" with common utensils
608 and foods (e.g., salt, sugar, spices, etc.) to obtain weights for portions and ingredients where
609 possible.

610

611 [Opinions, attitude, and acceptance \(OAA\) towards the study bouillon among adult household](#) 612 [members](#)

613 The OAA sub-study will employ a mixed methods approach (quantitative survey and focus
614 group discussions). OAA towards commercial bouillon will be evaluated with a questionnaire
615 during the observation period, and towards the study-provided bouillon with a similar
616 questionnaire once within the first 60 days and once within the final 60 days of the intervention
617 period. One round of focus group discussions (FGDs) will also be conducted among a subset of
618 participants who complete the OAA questionnaires to qualitatively assess OAA of the study-
619 supplied bouillon cubes. FGDs will be conducted in Dagbani following a pre-tested FGD guide
620 and audio-recorded.

621

622 Anthropometry

623 Anthropometric data will be collected by trained, standardized anthropometrists, following
624 protocols established by the Food and Nutrition Technical Assistance Project [42]. Children's
625 MUAC (left arm; UNICEF S0145620), standing height of all participants (SECA 217), and the
626 waist and hip circumference of WRA (SECA 201) will be measured to 0.1 cm precision. Weight
627 of all participants (lightly clothed) will be measured to 50 g precision (SECA 874). All
628 measurements will be collected in duplicate, and the average of the two measurements calculated
629 per participant for each outcome. If the two measurements differ by more than 0.1 kg (weight),
630 or 0.5 cm (MUAC, height, waist or hip circumference), the measurement will be repeated, and
631 the two closest measurements will be retained for data analysis.

632

633 Child development

634 Child development will be assessed with the Malawi Development Assessment Tool (MDAT)
635 [43], which measures four domains of development (gross motor, fine motor, language, and
636 personal-social), and the tablet-based Early Years Toolbox Go-No-Go Task which measures
637 executive function (EYT) [44]. Assessments will take place at a central data collection site or (if
638 necessary) in a low-distraction location at the participant's home. Characteristics of the home
639 environment and caregiver-child interaction will be assessed at a household visit with the Home
640 Observation Measurement of the Environment (HOME) tool [45]. To assess the test-retest
641 reliability of the EYT a convenience sample of 30 children will be asked to come back 1 week
642 later to repeat the EYT.

643

644 Prior to data collection, enumerators trained in child development assessment will be required to
645 take a written and practical assessment on the data collection procedures. Inter-rater reliability of
646 the enumerators will be assessed for the MDAT and the HOME to ensure consistency of data

647 collection. The MDAT and HOME were previously piloted in the study site and found to be
648 feasible for use in this setting.

649

650 Biological sample collection and laboratory analyses

651 *Capillary and venous blood collection*

652 At the pre-intervention RID-screening visit, capillary blood samples will be obtained from WRA
653 to measure hemoglobin and CRP concentrations using the QuikRead Go (Aidian Oy, Espoo,
654 Finland); malaria antigenemia will be measured by RDT (BioZEK, B.V., Apeldoorn,
655 Netherlands). At the post-intervention RID-screening visit, these measurements will be done
656 using venous blood that is collected for assessment of endline micronutrient status.

657

658 At baseline and endline assessments, venous blood samples will be collected from children and
659 WRA by trained laboratory technicians, following standard biological safety protocols and
660 procedures recommended by the International Zinc Nutrition Consultative Group (IZiNCG) [46].
661 Samples will be collected at a central location in each community (mobile biospecimen
662 collection site) in the early morning. WRA, but not children, will be asked to fast for at least 8
663 hours prior to their blood draw appointment; time of blood collection and last meal will be
664 recorded for all participants. At all blood sample events (baseline, endline 1 and endline 2), 7.5
665 ml of blood will be drawn from the antecubital vein into an evacuated, trace element-free
666 polyethylene blood collection tube containing lithium heparin (Sarstedt AG & Co, Numbrecht,
667 Germany; ref 01.1604.400). For all WRA at baseline and endline 2, as well as a subset of WRA
668 at endline 1, an additional 4.5 ml of blood will be drawn from the antecubital vein into an
669 evacuated serum blood collection tube (Sarstedt AG & Co, Numbrecht, Germany; ref
670 05.1104.100); this will occur prior to blood collection in the lithium heparin tube. In addition, if
671 WRA receive the vitamin A isotope dose at endline 2 (due to deferral), an additional 4.5 ml of

672 blood will be drawn from the antecubital vein into an evacuated serum blood collection tube
673 (Sarstedt AG & Co, Numbrecht, Germany; ref 05.1104.100) at a third time point. If the
674 phlebotomist is unable to obtain a venous blood sample after two attempts, a capillary sample
675 will be obtained by fingerstick and collected into a 200 µl microvette containing lithium heparin
676 (Sarstedt AG & Co, Numbrecht, Germany; ref 20.1292.100). Following blood collection, all
677 blood collection tubes will be placed into a battery-operated cold box (4 – 8°C) until processing.
678
679 Immediately following blood collection, point-of-care assessments will be performed using
680 whole blood remaining in the butterfly tubing or needle (or from the capillary sample); if
681 necessary, whole blood may be aliquoted from the lithium heparin blood collection tubes for the
682 RDTs. Hemoglobin will be measured using a portable photometer (Hemocue 301, HemoCue
683 AB, Angelholm, Sweden). Malaria antigenemia will be assessed with an RDT. Hematocrit (WRA
684 only) will be measured using the GCH-24 Hematocrit centrifuge (Globe Scientific, Mahwah,
685 New Jersey, USA). In addition, hemoglobin, hematocrit and zinc protoporphyrin (ZPP) will be
686 measured using the iCheck Anemia point-of-care device (Bioanalyt, Teltow, Germany).
687
688 Whole blood samples from the serum blood collection tubes will be allowed to clot for 30-60
689 minutes, after which time they will be centrifuged at 1097 x g (3100 RPM) for 10 minutes
690 (PowerSpin Centrifuge Model LX C856E; United Products & Instruments, Inc, Dayton, NJ).
691 Serum will be aliquoted for the measurement of concentrations of [¹²C]retinol, d6-retinol and
692 [¹³C₁₀]retinol and folate. From the lithium heparin blood collection tube, 100 µl of whole blood
693 will be aliquoted into a cryovial containing 1 ml of 1% ascorbic acid solution for the
694 measurement of folate concentration (to calculate erythrocyte folate) among WRA. The
695 remaining heparinized blood will be centrifuged within 8 h of collection at 1097 x g (3100 RPM)
696 for 10 minutes (PowerSpin Centrifuge Model LX C856E; United Products & Instruments, Inc,

697 Dayton, NJ). Plasma will be aliquoted into cryovials for the measurement of micronutrient status
698 (i.e., ferritin, soluble transferrin receptor [sTfR], retinol binding protein [RBP], retinol, zinc,
699 folate and B12) and indicators of systemic inflammation (i.e., CRP, and alpha-1-acid
700 glycoprotein, AGP).

701

702 Breast milk collection and processing

703 At baseline and endline assessments, breast milk samples will be collected from lactating women
704 using the “full milk sample” methodology [47] using the Medela Swing single electric breast
705 pump (Barr, Switzerland). Breast milk will be collected from the breast from which the infant
706 has not fed for a longer time (i.e., the breast that is ‘more full’), with a minimum of one hour
707 elapsed between the milk sample collection and previous feeding. Time of day and time since
708 last feed will be recorded. Fat will be measured in fresh milk in triplicate using the creatocrit
709 method (Creatocrit Plus Centrifuge; EKF Diagnostics) [48]. The milk sample will be mixed
710 well and ~6 ml will be aliquoted for the measurement of vitamins A and B12; the remainder of
711 the milk sample will be returned to the lactating woman to feed to her child.

712

713 Urine collection and processing

714 Urine samples will be collected from both WRA and children at baseline and endline 1
715 assessments. Among WRA only, spot urine samples will be collected on the day of the pre- and
716 post-intervention RID-screening visits (prior to retinol isotope dosing) to assess pregnancy status
717 based on rapid tests for human chorionic gonadotropin (HCG). At all time points, urine will be
718 aliquoted into cryovials for the measurement of iodine, sodium, potassium and creatinine
719 concentrations.

720

721 Stool collection and processing

722 Stool samples will be collected from children at baseline and endline 1. The child's caregiver
723 will be provided with stool sample collection kits (self-standing transport tube with screw cap
724 and spoon, absorbent pad and/or diaper, gloves, biohazard bags, soap) and requested to collect
725 the first available fresh stool sample from the child on the morning of the baseline visit, partially
726 filling the transport tube. In a randomly selected subset of participants, caregivers will also be
727 provided with a stool nucleic acid collection and preservation tube (Norgen Biotek; Ontario,
728 Canada), and requested to collect a small sample of stool into a second tube. Unpreserved stool
729 samples will be aliquoted into cryovials for the measurement of calprotectin; no processing will
730 be necessary for the microbiome analysis samples in the nucleic acid collection and preservation
731 tubes.

732

733 Biological sample storage

734 All biological sample aliquots will be stored in a battery-operated cold box (4 – 8°C) and
735 transported daily from the biospecimen collection site to the District Hospital at Tolon for
736 storage in a -86°C freezer, with regular temperature monitoring. Samples thus stored will be
737 periodically transported to the University of Ghana for longer-term frozen storage before
738 analysis. Samples to be analysed outside Ghana will be shipped by air on dry ice to the
739 respective labs, as described below.

740

741 Laboratory analysis

742 Plasma ferritin, sTfR, RBP, CRP, and AGP concentrations will be measured in duplicate using a
743 combined sandwich enzyme-linked immunosorbent assay (ELISA) technique at VitMin Lab
744 (Willstaett, Germany) [49]. Serum concentrations of d6-retinol, [¹²C]retinol and [¹³C₁₀]retinol
745 will be measured by liquid chromatography with tandem mass spectrometry (LC/MS/MS) at

746 Newcastle University (Newcastle, UK) [50]. Plasma [51] and breast milk [52] vitamin A
747 concentrations will be measured by high performance liquid chromatography (HPLC) at the
748 UCD (Davis, CA). Plasma zinc concentrations will be analyzed by inductively-coupled plasma
749 optical emission spectrophotometry (ICP-OES; Agilent 5100 SVDV, Santa Clara, CA) at the
750 University of California, San Francisco (UCSF) Benioff Children’s Hospital (Oakland, CA) [53].
751 Whole blood folate and serum/plasma folate will be analyzed by the US Centers for Disease
752 Control and Prevention (Atlanta, GA) and used to calculate erythrocyte folate concentrations
753 [54]. Vitamin B12 concentrations in plasma and breast milk, will be measured by the Western
754 Human Nutrition Research Center (Davis, CA). Urinary iodine concentration will be assessed
755 using a modification of the Sandell-Kolthoff reaction at the University of Ghana [31]. Urinary
756 sodium, potassium and creatinine concentrations will be analyzed at the UCSF Benioff
757 Children’s Hospital (Oakland, CA). Stool calprotectin will be analysed using a commercially
758 available kit and gut microbiota will be characterized by bacterial 16S rRNA sequencing at UCD
759 (Davis, CA). Novel indicators and other indicators of micronutrient status, growth and infection
760 may be assessed if funding becomes available, among participants who consented to the use of
761 their specimen for future research.

762

763 [Data management and analysis](#)

764 [Data management and confidentiality](#)

765 Data will be collected directly on tablets via forms developed to include pre-determined logic
766 checks and range validations using the SurveyCTO® program. Selected data collected on paper
767 forms will be double-entered. Data will be monitored daily by field supervisors. Weekly reports
768 for monitoring of key variables, including study enrollment, attrition, missing data/forms,
769 adherence, and selected quality control monitoring will be routinely reviewed by the research
770 team and field supervisors to identify action items (e.g., form corrections, refresher trainings,

771 participant visits to encourage adherence, data corrections, etc.). Study procedures are designed
772 so that all Personally Identifying Information is kept separately from all other data throughout
773 data collection, storage, and analysis and only accessible to a limited number of authorized
774 members of the research team.

775

776 Outcome definitions

777 For WRA and children, primary outcomes are hemoglobin concentrations and biomarkers of
778 status of iron (plasma ferritin and sTfR), zinc (plasma zinc), folate (plasma folate, erythrocyte
779 folate), vitamin A (total body stores of vitamin A [WRA only], serum retinol, plasma RBP), and
780 vitamin B12 (plasma B12) measured in venous blood samples. Pilot data indicated that vitamin
781 A deficiency was common among children but not WRA in the community; therefore, total body
782 vitamin A stores were selected as the vitamin A outcome for WRA because serum retinol is
783 expected to respond to increased vitamin A intake only when vitamin A stores are low [55]. For
784 lactating women, primary outcomes are concentrations of vitamin A (corrected for milk fat) and
785 vitamin B12 in human milk. Secondary outcomes for women and children include anemia and
786 prevalence of micronutrient deficiencies, malaria and inflammation (CRP and AGP), blood
787 pressure and hypertension, and urinary iodine and sodium. Additional secondary outcomes
788 include dietary intake of bouillon and micronutrients, and morbidity symptoms (all participants);
789 low milk micronutrient concentrations (lactating women); and child development and stool
790 calprotectin (children). **S1 and S2 (Supplemental Tables 1 and 2)** include detailed lists of
791 primary and secondary outcomes, and **S3 and S3 (Supplemental Tables 3 and 4)** specify the
792 micronutrient biomarker cutoffs to be used.

793

794 Data analysis

795 Statistical analysis plans (SAPs) will be developed and posted publicly prior to conducting any
796 data analysis. For each analysis, a flow diagram for participation will be prepared according to
797 CONSORT guidelines. In most cases, separate analyses will be conducted for each physiological
798 group. Because randomization will occur at the household level and only one individual per
799 physiological group will be enrolled per household, the participants will be considered
800 independent with repeated measurements on the same participant being accounted for with
801 robust standard errors [56]. Additionally, a variable representing the recruitment site of each
802 participant will be included as a control covariate.

803
804 The primary analysis will be based on a complete-case intention to treat framework and analysed
805 as a pre-post study design, controlling for baseline measure of the outcome [57]. Testing will be
806 two-sided superiority testing. For continuous outcomes, this will follow an ANCOVA approach
807 with non-normal outcomes transformed prior to analysis (typically log transformed). For binary
808 outcomes, we will use either logistic regression to estimate odds ratios or binomial log-link /
809 modified poisson regression to estimate risk ratios (approach will be pre-specified in each SAP).
810 In addition to the outcome-specific testing, certain analyses may use a multivariate analysis to
811 examine the simultaneous impact of the intervention on multiple outcomes (approach will be
812 pre-specified in each SAP).

813
814 In keeping with the randomized design of the study, we will rely on the minimally adjusted
815 analysis (only controlling for baseline measure and recruitment site) as our primary analysis. For
816 selected biomarkers (for example, plasma ferritin), the primary analysis will use inflammation-
817 corrected outcomes and/or a minimally adjusted analysis that includes markers of inflammation
818 (CRP and AGP) at each time point, if biologically relevant and if the outcome is associated with

819 the markers of inflammation in bivariate analyses (details will be pre-specified in each SAP). In
820 a secondary analysis, we will estimate adjusted parameters by including variables that are
821 strongly associated with the outcome to potentially improve the precision of our estimates (i.e.,
822 decrease the standard errors). Variable selection approach will be pre-specified in each SAP.
823 Additionally, pre-specified effect modification testing will be conducted by including an
824 interaction term in minimally adjusted models.

825
826 Substantial attrition (>20% loss) after randomization will trigger sensitivity analyses to assess
827 the impact of missingness on inference. This will be conducted either by multiple imputation or
828 inverse probability of censoring-weighted analysis (pre-specified in each SAP). We will also
829 conduct a per protocol analysis using data on adherence to identify the subgroup of participants
830 in “high compliance” households.

831
832 A qualitative SAP will also be developed for analysis of the OAA focus group data. FGD
833 transcripts will be translated and transcribed to English by two independent parties. A codebook
834 will be developed, and two researchers will independently code the transcripts with Cohen’s
835 Kappa used to assess intercoder reliability (ICR); transcripts with an ICR <0.6 [58] (less than
836 moderate agreement) will trigger discussion and recoding. Selection of qualitative themes will
837 occur through discussions with the greater research team.

838

839 **Sample size**

840 Detection of an effect size of 0.26 SDs was selected based on calculations of the change in total
841 body vitamin A stores among WRA and iron stores among women and children over the 9-mo
842 trial duration; details are presented in the Technical Appendix to the study protocol, available at
843 <https://osf.io/t3zrn/>). Assuming this effect size and a level of significance of $\alpha=0.05$ with 80%

844 power we will target an analytic sample size of 234 per physiological group per intervention group.

845 Although this sample size calculation is based on analysis of a single cross-sectional measurement,

846 final models will incorporate a baseline measurement and repeated endline measurements to

847 provide additional statistical power.

848

849 Attrition will be accounted for at multiple time points due to the multi-staged study design

850 involving recruitment, screening and baseline study visits prior to randomization to study group.

851 Overall attrition rates were estimated using cross-sectional pilot survey data and are set at ~32%

852 for children 2-5 y of age and lactating women and at 54% for WRA to account for additional

853 participant exclusion due to pregnancy during the intervention period. Therefore, the recruitment

854 targets will be 690 lactating women, 690 children 2-5 y of age, and 1028 WRA; each split evenly

855 by intervention group.

856

857 [Safety and ethics](#)

858 [Ethical and institutional approvals](#)

859 This trial, including the investigational product, has been reviewed and approved by the Ghana

860 Food and Drug Authority (FDA, clinical trial certificate number FDA/CT/2213), the Ghana

861 Health Service Ethical Review Committee (GHS- ERC) (GHSERC ID: 024/11/21), and the

862 UCD, USA, Institutional Review Board (IRB) Human Subjects Committee (IRB ID: 1837253).

863 The trial was registered on ClinicalTrials.gov (NCT05178407) and the Pan-African Clinical Trial

864 Registry (PACTR202206868437931). Any protocol modifications will be submitted to the FDA,

865 GHS-ERC, and UCD IRB for review, and the trial registries will be updated with approved

866 modifications.

867

868 We will seek permission from the Regional (Northern Region) and District (Tolon and
869 Kumbungu) Directors of Health of Services as well as community leaders before recruiting
870 participants into the study. With the assistance of the local health personnel, we will then hold
871 general informational meetings with community leaders of each of the communities in the
872 catchment area about the objectives, methods and possible benefits of the study for the study
873 participants and communities.

874

875 [Safety monitoring](#)

876 A Data and Safety Monitoring Board (DSMB) will be established for this project. The board will
877 consist of 5 members (3 in Ghana, 2 international) not otherwise involved in this study, without
878 competing interests, and who are experts in child health and nutrition research (with one or more
879 members with expertise in medicine, infectious disease, and/or biostatistics). The DSMB will
880 meet at predefined intervals (with intermediate meetings added if deemed necessary by the
881 committee or investigators) to review study progress (including recruitment, loss to follow up,
882 and protocol compliance) and safety monitoring data. The DSMB may recommend actions or
883 modifications, which will be addressed by the study investigators, who will then notify and/or
884 seek approval from the relevant ethical review committees, as appropriate. Blinded interim
885 analysis of severe adverse events (SAE) and selected adverse events (AE, such as diarrhea and
886 malaria) will be conducted for safety considerations and reviewed by the DSMB. No interim
887 analyses related to intervention efficacy are pre-planned.

888

889 The GHS-ERC, Ghana FDA (which regulates clinical trials in Ghana), UCD IRB, or the DSMB
890 may request unblinded safety data to discuss in closed sessions. Unblinding of the intervention
891 group may be requested if there is a pattern of SAEs which may be related to study treatment

892 where the DSMB or other regulatory agency feels there is “potential for harm”. In this case, the
893 randomization code will be provided by one of the two code keepers.

894

895 Suspected SAEs, such as deaths or hospitalization of study participants, will be reported
896 immediately to the principal investigators, who will notify the GHS-ERC, the Ghana
897 FDA, the UCD IRB, and the DSMB in a timely manner as required by their policies;
898 these agencies and committees will then determine whether modifications are required to
899 ensure participant safety and welfare.

900

901 To minimize chance of exposure to COVID-19, we have developed Standard Operating
902 Procedures for our field staff and study participants based on recommendations by the
903 Government of Ghana and the GHS-ERC. A physician assistant will refer participants for
904 medical advice and treatment if they are found to have severe malnutrition (children), severe
905 anemia (children or WRA), malaria infection (children or WRA), hypertension (WRA), or other
906 signs of severe illness. Morbidity will be monitored at biweekly home visits and participants
907 will be referred for follow up treatment based on symptoms reported during these visits. The
908 cost of the national health insurance annual premium will be covered for all randomized
909 participants.

910

911 Participants who become pregnant will be excluded from the study for scientific reasons (effects
912 of pregnancy on micronutrient biomarker concentrations, and lack of validation of the RID
913 method for pregnant women). Although exclusion of study participants due to pregnancy is not
914 based on any safety concerns, we will follow all index participants who become pregnant until
915 the resolution of their pregnancy (miscarriage, still birth, live birth, etc.) via telephone interview
916 to monitor pregnancy outcomes.

917

918 [Trial management](#)

919 The trial will be implemented by investigators at the University of Ghana and UCD, who jointly
920 developed the trial protocol and all data collection procedures and instruments. Data collection
921 staff will be hired by the University of Ghana, including supervisors, anthropometrists,
922 phlebotomist and laboratory staff, nurse, medical assistant, enumerators, an information
923 technology manager, data entry clerks, and an inventory manager. Staff will participate in
924 intensive training on research ethics, the study protocol, and data collection procedures,
925 including didactic sessions with accompanying quizzes, demonstrations, and pilot-testing. UCD
926 staff will support the study implementation through in-person supervision and remote data
927 monitoring. Investigators from both universities meet weekly to discuss study progress. As the
928 trial is subject to audit at the discretion of the Ghana FDA, the study investigators have
929 contracted with a Local Monitor who is responsible for conducting Good Clinical Practices
930 training of field staff, assessing and approving site readiness to begin data collection, and
931 conducting regular visits to the study site to monitor study implementation. The Regional
932 (Northern Region) and District (Tolon and Kumbungu Districts) Directors of Health were
933 informed about the project on a regular basis throughout pilot research conducted in 2020-2022,
934 and these interactions will continue through trial implementation and results dissemination.

935

936 This study is part of a larger initiative supported by the Bill & Melinda Gates Foundation that is
937 focused on generating evidence to inform discussions of bouillon fortification policy among
938 countries in West Africa. Helen Keller International received support from the Bill & Melinda
939 Gates Foundation for research and policy engagement activities related to bouillon fortification
940 in West Africa (INV-007916), that includes supporting the activities of multi-stakeholder
941 bouillon Country Working Groups in Nigeria, Senegal, and Burkina Faso. Helen Keller

942 International also administers a subaward to UCD for conduct of this trial as well as a portfolio
943 of modelling research focused on estimating the impacts, costs, and cost-effectiveness of
944 micronutrient-fortified bouillon. The larger initiative includes research on technical aspects of
945 bouillon fortification by the Commonwealth Scientific and Industrial Research Organisation
946 (CSIRO) and Research Institutes of Sweden AB (RISE), in collaboration with a consortium of
947 representatives of companies involved in production of bouillon or micronutrient fortificants.
948 These consortium partners developed the non-proprietary unfortified bouillon cube which served
949 as the base formulation for the multiple micronutrient-fortified cubes tested in this trial. All
950 members of this large initiative were given the opportunity to review the study protocol and
951 provide comments. However, the trial investigators selected the micronutrient levels in the
952 investigational bouillon cubes and retain all final decision-making authority related to all aspects
953 of study design, implementation, and dissemination (subject to requirements of the Ghana FDA
954 and ethical committees). Regular updates on study progress will be provided to consortium
955 partners through email and virtual meetings.

956

957 [Dissemination](#)

958 The results from this study will be disseminated in national and international conferences and
959 published as Open Access publications in peer-reviewed journals. Authorship will be determined
960 based on international criteria [59]. Dissemination workshops will be held with national
961 stakeholders in Ghana, and with regional and district stakeholders in the study area. Study results
962 will also be disseminated through the network of bouillon-related partners and stakeholders
963 associated with this project, with particular focus on the West Africa region. Specific
964 dissemination activities will be informed by discussions of the trial Dissemination Advisory
965 Group, convened by University of Ghana, UCD, and Helen Keller International, and consisting
966 of representatives from academia and the public sector in Ghana, Burkina Faso, Senegal, and

967 Nigeria. Publications, Statistical Analysis Plans, and other study resources will be posted on
968 Open Science Framework (<https://osf.io/t3zrn/>).

969

970 [Trial status](#)

971 Recruitment began on January 16, 2023. Data collection is expected to be completed in mid-
972 2024.

973

974 **Discussion**

975

976 The burden of micronutrient deficiencies continues to be unacceptably high in many parts of the
977 world. In West Africa, bouillon fortification has the potential to reduce this burden. This study
978 will generate the first information on the effects of micronutrient-fortified bouillon cube on the
979 micronutrient content of human milk and the micronutrient status of women and young children,
980 populations that are vulnerable to micronutrient deficiency. As such, the study serves as “proof
981 of concept” regarding the potential efficacy of micronutrient-fortified bouillon to achieve
982 adequate micronutrient status and reduce the consequences of deficiency. This information will
983 be useful to national, regional and global stakeholders involved in assessing the potential for
984 fortified bouillon cubes to contribute to addressing deficiencies in one or more of the
985 micronutrients examined.

986

987 Research and policy discussions related to bouillon fortification must consider the
988 generalizability of study results, with specific attention to the 1) study population diets and other
989 characteristics, 2) micronutrient concentrations in the fortified bouillon, and 3) differences
990 between research and programmatic/commercial contexts for bouillon. The trial is being
991 conducted in a community with frequent bouillon intake and high prevalence of micronutrient

992 deficiency, and the micronutrient concentrations of the cubes tested in this trial were selected as
993 those likely to be both efficacious (i.e., increasing micronutrient status) and safe (i.e. not causing
994 adverse effects) in this context. While these characteristics also apply to many communities
995 throughout West Africa, there is great variation within and across countries in bouillon
996 consumption and micronutrient deficiency [14, 16]. Discussions on bouillon fortification
997 standards must consider the impacts on population subgroups with both adequate and inadequate
998 micronutrient intake, and populations with varying bouillon consumption.

999
1000 Where countries move ahead with bouillon fortification standards (or at the regional level, as
1001 cooking oil and wheat flour fortification are implemented in West Africa), decisions around
1002 selection of the desired micronutrient concentrations in the standards should use population-
1003 specific data on dietary intake as a starting point [29] rather than the levels tested in this trial.
1004 Micronutrient concentrations in standards may be different than those tested in this study, and
1005 standards may also include micronutrients that were not tested in this study. Modelling of
1006 dietary intake or household consumption surveys data can help inform what micronutrients and
1007 what concentrations will meet dietary gaps for target population subgroups while minimizing
1008 intakes above the UL [60]. Standards must also consider technical and commercial constraints,
1009 such as required changes to product formulas and manufacturing processes, premix cost, and the
1010 ability to pass along some or all of these costs to bouillon consumers. Moreover, it is important
1011 to note that in the trial context we are maintaining bouillon cubes in climate-controlled storage
1012 conditions (up to the point of delivery to the household) to ensure acceptability and micronutrient
1013 stability of the cubes; these characteristics will have to be confirmed under commercial
1014 conditions.

1015

1016 In this trial, bouillon is regularly delivered to participant households, free of charge. The
1017 household bouillon ration is capped to avoid extra-household sharing and artificially inflating the
1018 impact of fortified bouillon if bouillon consumption were to increase due to providing bouillon
1019 free of charge to participating households. Nevertheless, in a program setting the effects of
1020 fortified bouillon may be diluted if less-expensive, unfortified bouillon products are available or
1021 if households reduce their bouillon consumption in response to price increases due to
1022 fortification. Moreover, program compliance with standards is a challenge with other types of
1023 large-scale food fortification programs [11] and especially for easily imported products, therefore
1024 highlighting the need for effective monitoring and evaluation programs to secure the
1025 effectiveness of any future bouillon fortification programs.

1026

1027 Given the wide and equitable reach of bouillon in West Africa, including among populations at
1028 risk of micronutrient deficiencies who do not consume other fortified foods, addition of
1029 micronutrients to bouillon holds great potential to reduce deficiencies. This study will provide
1030 evidence regarding the efficacy of bouillon fortification in a specific West African context for
1031 improving micronutrient status. This new evidence will inform ongoing discussions on large-
1032 scale food/condiment fortification and other strategies to reduce the burden of micronutrient
1033 deficiencies and their consequences in the region.

1034

1035 **Acknowledgments**

1036 We gratefully acknowledge the contributions of the local medical monitor Dr. Mohammed Hafiz
1037 Kanamu (Tamale Teaching Hospital) and the local study implementation monitors Michael Ntiri
1038 and Morrison Asiamah. We thank Dr. Bess Caswell (USDA Western Human Nutrition Research
1039 Center) and Boateng Bannerman (University of Ghana, Legon) for assistance with study blinding
1040 and Professor Sam Newton (Kwame Nkrumah University of Science and Technology (KNUST)),

1041 Dr. Justice Moses K. Aheto (University of Ghana, Legon), Dr. Edward Frongillo (University of
1042 South Carolina), Dr. Agarthah Ohemeng (University of Ghana, Legon), and Prof Andrew
1043 Prendergast (Queen Mary University of London) for serving on the Data and Safety Monitoring
1044 Board.

1045
1046 We thank GB foods for producing the trial-specific micronutrient-fortified bouillon cubes for this
1047 study, particularly Félix Sancho, Juan Carlos Velasco, and Patricia Lopez. We thank DSM for
1048 preparing the micronutrient premix and Symrise for preparing the specific flavouring used in the
1049 trial cubes. Colleagues at the Commonwealth Scientific and Industrial Research Organisation
1050 (CSIRO), along with members of a consortium created the model bouillon formulation used in this
1051 study and advised on technical issues related to bouillon storage and management.

1052
1053 The Bill & Melinda Gates Foundation Design Analyze Communicate (DAC) team provided
1054 helpful comments on an early version of the study protocol and facilitated trial design simulations
1055 by Mediana. We further appreciate the technical and overall guidance of Dipika Matthias (PATH),
1056 Ann Tarini (independent consultant), and colleagues at Helen Keller International. We
1057 acknowledge the UCSF MLK Cores Research Facility for support with sample analysis plans.
1058 Finally, we thank Yakubu Adams and Felix Kyereh (University of Ghana) and Dr. Lindsay Allen
1059 (USDA) for contributions to study preparations, Dr. Elizabeth Prado (UC Davis) for guidance on
1060 child development assessments, Lauren Thompson (UC Davis) for assistance with stool collection
1061 protocols, Dr. Michael Green (The Pennsylvania State University), Dr. Anthony Oxley and Dr.
1062 Alice Goddard (Newcastle University) for support with RID assessment.

1063 **Online Supporting Material**

- 1064
- 1065 S1. Table of primary outcomes
- 1066 S2. Table of secondary outcomes
- 1067 S3. Table of specification and definitions of hemoglobin and micronutrient biomarker variables
- 1068 for children 2-5 years of age
- 1069 S4. Table of specification and definitions of hemoglobin and micronutrient biomarker variables
- 1070 for non-pregnant, non-lactating women of reproductive age
- 1071 S5. Supplemental Methods: Inclusion, Exclusion, and Deferral Criteria

1072

1073

1074

1075 **References**

1076

- 1077 1. Stevens GA, Beal T, Mbuya MNN, Luo H, Neufeld LM. Micronutrient deficiencies among
- 1078 preschool-aged children and women of reproductive age worldwide: a pooled analysis of
- 1079 individual-level data from population-representative surveys. *Lancet Glob Health*.
- 1080 2022;10(11):e1590-e9. Epub 2022/10/15. doi: 10.1016/s2214-109x(22)00367-9. PubMed PMID:
- 1081 36240826.
- 1082 2. Stevens G, Bennett J, Hennocq Q, Lu Y, De-Regil L, Rogers L, et al. Trends and mortality
- 1083 effects of vitamin A deficiency in children in 138 low-income and middle-income countries
- 1084 between 1991 and 2013: a pooled analysis of population-based surveys. *Lancet Glob Health*.
- 1085 2015;3:e528-36.
- 1086 3. Rogers LM, Cordero AM, Pfeiffer CM, Hausman DB, Tsang BL, De-Regil LM, et al.
- 1087 Global folate status in women of reproductive age: a systematic review with emphasis on

- 1088 methodological issues. *Ann N Y Acad Sci.* 2018;1431(1):35-57. Epub 2018/09/22. doi:
1089 10.1111/nyas.13963. PubMed PMID: 30239016; PubMed Central PMCID: PMC6282622.
- 1090 4. Bailey RL, West KP, Jr., Black RE. The epidemiology of global micronutrient deficiencies.
1091 *Ann Nutr Metab.* 2015;66 Suppl 2:22-33. Epub 2015/06/06. doi: 10.1159/000371618. PubMed
1092 PMID: 26045325.
- 1093 5. Alderman H. The economic cost of a poor start to life. *Journal of developmental origins of*
1094 *health and disease.* 2010;1(1):19-25. Epub 2010/02/01. doi: 10.1017/s2040174409990158.
1095 PubMed PMID: 25142929.
- 1096 6. Global Fortification Data Exchange [16/05/2023]. Available from:
1097 <http://www.fortificationdata.org>.
- 1098 7. Wegmüller R, Bentil H, Wirth JP, Petry N, Tanumihardjo SA, Allen L, et al. Anemia,
1099 micronutrient deficiencies, malaria, hemoglobinopathies and malnutrition in young children and
1100 non-pregnant women in Ghana: Findings from a national survey. *PLoS One.*
1101 2020;15(1):e0228258. Epub 2020/01/31. doi: 10.1371/journal.pone.0228258. PubMed PMID:
1102 31999737; PubMed Central PMCID: PMC6991996 are responsible for the views expressed in
1103 this publication and they do not necessarily represent the decisions, policy or views of UNICEF.
1104 This does not alter our adherence to PLOS ONE policies on sharing data and materials.'.
- 1105 8. University of Ghana, GroundWork, University of Wisconsin-Madison, KEMRI-Wellcome
1106 Trust, UNICEF. *Ghana Micronutrient Survey 2017.* Accra, Ghana: 2017.
- 1107 9. Nyumuah RO, Hoang TC, Amoafu EF, Agble R, Meyer M, Wirth JP, et al. Implementing
1108 large-scale food fortification in Ghana: lessons learned. *Food Nutr Bull.* 2012;33(4 Suppl):S293-
1109 300. Epub 2013/03/01. doi: 10.1177/15648265120334s305. PubMed PMID: 23444710.
- 1110 10. Univ Ghana/GroundWork/Univ Wisconsin-Madison/KEMRI/UNICEF. *Ghana*
1111 *Micronutrient Survey [Internet].* UNICEF-Accra, Accra, Ghana [cited 2019-05-21]. Available

- 1112 from: http://groundworkhealth.org/wp-content/uploads/2018/06/UoG-GroundWork_2017-
1113 [GHANA-MICRONUTRIENT-SURVEY_Final_180607.pdf](http://groundworkhealth.org/wp-content/uploads/2018/06/UoG-GroundWork_2017-GHANA-MICRONUTRIENT-SURVEY_Final_180607.pdf). 2017.
- 1114 11. Osendarp SJM, Martinez H, Garrett GS, Neufeld LM, De-Regil LM, Vossenaar M, et al.
1115 Large-Scale Food Fortification and Biofortification in Low- and Middle-Income Countries: A
1116 Review of Programs, Trends, Challenges, and Evidence Gaps. *Food Nutr Bull.* 2018;39(2):315-31.
1117 Epub 2018/05/26. doi: 10.1177/0379572118774229. PubMed PMID: 29793357; PubMed Central
1118 PMCID: PMCPMC7473077.
- 1119 12. Matthias D, McDonald CM, Archer N, Engle-Stone R. The Role of Multiply-Fortified
1120 Table Salt and Bouillon in Food Systems Transformation. *Nutrients.* 2022;14(5). Epub 2022/03/11.
1121 doi: 10.3390/nu14050989. PubMed PMID: 35267964; PubMed Central PMCID:
1122 PMCPMC8912775.
- 1123 13. Garcia-Casal MN, Peña-Rosas JP, McLean M, De-Regil LM, Zamora G. Fortification of
1124 condiments with micronutrients in public health: from proof of concept to scaling up. *Ann N Y*
1125 *Acad Sci.* 2016;1379(1):38-47. Epub 2016/08/11. doi: 10.1111/nyas.13185. PubMed PMID:
1126 27508517.
- 1127 14. Engle-Stone R, Adams KP, Kumordzie SM, Luo H, Wessells K, Adu-Afarwuah S, et al.,
1128 editors. Analyses using national survey data from Cameroon, Haiti, and Ghana indicate the
1129 potential for bouillon fortification to help fill dietary gaps for 5 nutrients2021: Current
1130 Developments in Nutrition.
- 1131 15. Engle-Stone R, Nankap M, Ndjebayi AO, Brown KH. Simulations based on representative
1132 24-h recall data predict region-specific differences in adequacy of vitamin A intake among
1133 Cameroonian women and young children following large-scale fortification of vegetable oil and
1134 other potential food vehicles. *J Nutr.* 2014;144(11):1826-34.
- 1135 16. Hess SY, Brown KH, Sablah M, Engle-Stone R, Aaron GJ, Baker SK. Results of
1136 Fortification Rapid Assessment Tool (FRAT) surveys in sub-Saharan Africa and suggestions for

- 1137 future modifications of the survey instrument. *Food Nutr Bull.* 2013;34(1):21-38. Epub
1138 2013/06/19. doi: 10.1177/156482651303400104. PubMed PMID: 23767278.
- 1139 17. Kumordzie SK, Adams KP, Arnold CD, Tan X, Vosti SA, Engle-Stone R. Assessment of
1140 the potential Impact of bouillon fortification on micronutrient Intakes in Ghana using a household
1141 expenditure survey. Submission to Micronutrient Forum 2020 conference:. 2019.
- 1142 18. Klassen-Wigger P, Geraets M, Messier MC, Detzel P, Lenoble HP, Barclay DV. Chapter
1143 39 - Micronutrient fortification of bouillon cubes in Central and West Africa. *Food Fortification in
1144 a Globalized World*: Academic Press; 2018. p. 363-72.
- 1145 19. Spohrer R, Knowles J, Jallier V, Ndiaye B, Indorf C, Guinot P, et al. Estimation of
1146 population iodine intake from iodized salt consumed through bouillon seasoning in Senegal. *Ann
1147 N Y Acad Sci.* 2015;1357:43-52. Epub 2016/01/16. doi: 10.1111/nyas.12963. PubMed PMID:
1148 26767583.
- 1149 20. Abizari AR, Dold S, Kupka R, Zimmermann MB. More than two-thirds of dietary iodine in
1150 children in northern Ghana is obtained from bouillon cubes containing iodized salt. *Public Health
1151 Nutr.* 2017;20(6):1107-13. Epub 2016/12/03. doi: 10.1017/s1368980016003098. PubMed PMID:
1152 27903312.
- 1153 21. Engle-Stone R, Nankap M, Ndjebayi AO, Brown KH. Simulations based on representative
1154 24-h recall data predict region-specific differences in adequacy of vitamin A intake among
1155 Cameroonian women and young children following large-scale fortification of vegetable oil and
1156 other potential food vehicles. *J Nutr.* 2014;144(11):1826-34. Epub 2014/10/22. doi:
1157 10.3945/jn.114.195354. PubMed PMID: 25332482.
- 1158 22. Vosti SA, Kagin J, Engle-Stone R, Luo H, Tarini A, Clermont A, et al. Strategies to
1159 achieve adequate vitamin A intake for young children: Options for Cameroon. *Ann N Y Acad Sci.*
1160 2020;1465(1):161-80. doi: 10.1111/nyas.14275.

- 1161 23. Luo H, Stewart CP, Brown KH, Engle-Stone R. Predicted effects of current and potential
1162 micronutrient intervention programs on adequacy of iron intake in a national sample of women and
1163 young children in Cameroon. Micronutrient Forum; Cancun, Mexico 2016.
- 1164 24. Green MH, Ford JL, Green JB, Berry P, Boddy AV, Oxley A, et al. A Retinol Isotope
1165 Dilution Equation Predicts Both Group and Individual Total Body Vitamin A Stores in Adults
1166 Based on Data from an Early Postdosing Blood Sample. *J Nutr.* 2016;146(10):2137-42. Epub
1167 2016/08/12. doi: 10.3945/jn.116.233676. PubMed PMID: 27511937; PubMed Central PMCID:
1168 PMC5037874.
- 1169 25. Affairs DoEaS. Designing household survey samples: Practical guidelines. New York:
1170 United Nations, 2005 Contract No.: ST/ESA/STAT/SER.F/98.
- 1171 26. Friesen VM, Jungjohann S, Mbuya MNN, Harb J, Visram A, Hug J, et al. Fortification
1172 Assessment Coverage Toolkit (FACT) Manual. Global Alliance for Improved Nutrition (Geneva)
1173 and Oxford Policy Management (Oxford), 2019.
- 1174 27. Green MH, Green JB. Use of Model-Based Compartmental Analysis and Theoretical Data
1175 to Further Explore Choice of Sampling Time for Assessing Vitamin A Status in Groups and
1176 Individual Human Subjects by the Retinol Isotope Dilution Method. *J Nutr.* 2021;151(7):2068-74.
1177 Epub 2021/04/10. doi: 10.1093/jn/nxab061. PubMed PMID: 33834213; PubMed Central PMCID:
1178 PMC8245873.
- 1179 28. Kumordzie SM, Davis JN, Adams KP, Tan X, Adu-Afarwuah S, Wessells K, et al.
1180 Understanding patterns and drivers of bouillon use in Northern Ghana to inform fortification
1181 planning. *Curr Dev Nutr.* 2021;5:655.
- 1182 29. Allen L, de Benoist B, Dary O, Hurrell R, editors. Guidelines on food fortification with
1183 micronutrients. Geneva: World Health Organization; 2006.
- 1184 30. Hackl L, Cercamondi CI, Zeder C, Wild D, Adelman H, Zimmermann MB, et al.
1185 Cofortification of ferric pyrophosphate and citric acid/trisodium citrate into extruded rice grains

- 1186 doubles iron bioavailability through in situ generation of soluble ferric pyrophosphate citrate
1187 complexes. *The American journal of clinical nutrition*. 2016;103(5):1252-9. Epub 2016/04/08. doi:
1188 10.3945/ajcn.115.128173. PubMed PMID: 27053382.
- 1189 31. Global Alliance for Improved Nutrition (GAIN), Ghana Health Service, UNICEF. National
1190 Iodine Survey Report Ghana 2015. 2017.
- 1191 32. Kumordzie SM, Wessells K, Becher E, Davis JN, Arnold CD, Tan X, et al. Acceptability
1192 of multiple micronutrient-fortified bouillon cubes among women in 2 districts in the northern
1193 region of Ghana. *Curr Dev Nutr*. 2022;6(Suppl 1):586.
- 1194 33. Food and Nutrition Board (FNB) Institute of Medicine (IOM). Dietary Reference Intakes
1195 for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese,
1196 Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington D.C.: National Academy Press,
1197 2001.
- 1198 34. Coates J, Swindale A, Bilinsky P. Household Food Insecurity Access Scale (HFIAS) for
1199 Measurement of Household Food Access: Indicator Guide (v. 3). Washington, D.C.: FHI
1200 360/FANTA, 2007.
- 1201 35. Young SL, Boateng GO, Jamaluddine Z, Miller JD, Frongillo EA, Neilands TB, et al. The
1202 Household Water InSecurity Experiences (HWISE) Scale: development and validation of a
1203 household water insecurity measure for low-income and middle-income countries. *BMJ Glob
1204 Health*. 2019;4(5):e001750. Epub 2019/10/23. doi: 10.1136/bmjgh-2019-001750. PubMed PMID:
1205 31637027; PubMed Central PMCID: PMC6768340.
- 1206 36. Organization WH. STEPS Instrument version 3.2 [Internet]. STEPwise Approach to NCD
1207 Risk Factor Surveillance (STEPS) [cited 2022 April 29]. Available from:
1208 <https://www.who.int/teams/noncommunicable-diseases/surveillance/systems-tools/steps>.

- 1209 37. Indicators for assessing infant and young child feeding practices: definitions and
1210 measurement methods. Geneva: World Health Organization and United Nations Children's Fund
1211 (UNICEF), 2021.
- 1212 38. Herforth AW, Wiesmann D, Martínez-Steele E, Andrade G, Monteiro CA. Introducing a
1213 Suite of Low-Burden Diet Quality Indicators That Reflect Healthy Diet Patterns at Population
1214 Level. *Curr Dev Nutr.* 2020;4(12):nzaa168. Epub 2020/12/22. doi: 10.1093/cdn/nzaa168. PubMed
1215 PMID: 33344879; PubMed Central PMCID: PMC7723758.
- 1216 39. Birch LL, Fisher JO, Grimm-Thomas K, Markey CN, Sawyer R, Johnson SL.
1217 Confirmatory factor analysis of the Child Feeding Questionnaire: a measure of parental attitudes,
1218 beliefs and practices about child feeding and obesity proneness. *Appetite.* 2001;36(3):201-10.
1219 Epub 2001/05/19. doi: 10.1006/appe.2001.0398. PubMed PMID: 11358344.
- 1220 40. Gibson RS, Ferguson EL. An interactive 24-hour recall for assessing the adequacy of iron
1221 and zinc intakes in developing countries: Washington, DC and Cali, Colombia: International Food
1222 Policy Research Institute (IFPRI) and International Center for Tropical Agriculture (CIAT); 2008.
- 1223 41. Caswell BL, Arnold CD, Engle-Stone R, Davis JN, Olney DK, Stewart CP. Open Dietary
1224 Recall System (OpenDRS): An open-access, tablet-based 24-hour dietary recall tool. in review.
1225 2023.
- 1226 42. Cashin K, Oot L. Guide to Anthropometry. A practical tool for program planners,
1227 managers, and implementers. Washington, D.C.: Food and Nutrition Technical Assistance III
1228 Project (FANTA)/FHI 360, 2018.
- 1229 43. Gladstone M, Lancaster G, Umar E, Nyirenda M, Kayira E, van den Broek N, et al. The
1230 Malawi Developmental Assessment Tool (MDAT): The creation, validation, and reliability of a
1231 tool to assess child development in rural African settings. *PloS Med.* 2010;7:e1000273.
- 1232 44. Howard SJ, Melhuish E. An Early Years Toolbox for Assessing Early Executive Function,
1233 Language, Self-Regulation, and Social Development: Validity, Reliability, and Preliminary

- 1234 Norms. *J Psychoeduc Assess*. 2017;35(3):255-75. Epub 2017/05/16. doi:
1235 10.1177/0734282916633009. PubMed PMID: 28503022; PubMed Central PMCID:
1236 PMCPMC5424850.
- 1237 45. Caldwell BM, Bradley RH. Home observation for measurement of the environment:
1238 administration manual. Family & Human Dynamics Research Institute, Arizona State University,
1239 2003.
- 1240 46. International Zinc Nutrition Consultative Group (IZiNCG). Assessment of the risk of zinc
1241 deficiency in populations and options for its control. Hotz C, Brown KH, eds. *Food and Nutrition*
1242 *Bulletin*. 2004;25 (suppl 2):S91-204.
- 1243 47. Stoltzfus R, Underwood B. Breast-milk vitamin A as an indicator of vitamin A status of
1244 women and infants. *Bull World Health Organ*. 1995;73:703-11.
- 1245 48. Lucas A, Gibbs JA, Lyster RL, Baum JD. Creamatocrit: simple clinical technique for
1246 estimating fat concentration and energy value of human milk. *Br Med J*. 1978;1(6119):1018-20.
1247 Epub 1978/04/22. PubMed PMID: 638579; PubMed Central PMCID: PMCPMC1604026.
- 1248 49. Erhardt JG, Estes JE, Pfeiffer CM, Biesalski HK, Craft NE. Combined measurement of
1249 ferritin, soluble transferrin receptor, retinol binding protein, and C-reactive protein by an
1250 inexpensive, sensitive, and simple sandwich enzyme-linked immunosorbent assay technique. *J*
1251 *Nutr*. 2004;134(11):3127-32. Epub 2004/10/30. doi: 10.1093/jn/134.11.3127. PubMed PMID:
1252 15514286.
- 1253 50. Engle-Stone R, Miller JC, Reario MFD, Arnold CD, Stormer A, Lafuente E, et al. Filipino
1254 Children with High Usual Vitamin A Intakes and Exposure to Multiple Sources of Vitamin A
1255 Have Elevated Total Body Stores of Vitamin A But Do Not Show Clear Evidence of Vitamin A
1256 Toxicity. *Curr Dev Nutr*. 2022;6(8):nzac115. Epub 2022/09/06. doi: 10.1093/cdn/nzac115.
1257 PubMed PMID: 36060221; PubMed Central PMCID: PMCPMC9429969.

- 1258 51. Bieri J, Tolliver T, Catignani G. Simultaneous determination of alpha-tocopherol and
1259 retinol in plasma or red cells by high pressure liquid chromatography. *The American journal of*
1260 *clinical nutrition*. 1979;32(10):2143-9. doi: 10.1093/ajcn/32.10.2143.
- 1261 52. Turner T, Burri BJ, Jamil KM, Jamil M. The effects of daily consumption of beta-
1262 cryptoxanthin-rich tangerines and beta-carotene-rich sweet potatoes on vitamin A and carotenoid
1263 concentrations in plasma and breast milk of Bangladeshi women with low vitamin A status in a
1264 randomized controlled trial. *The American journal of clinical nutrition*. 2013;98(5):1200-8. Epub
1265 2013/09/06. doi: 10.3945/ajcn.113.058180. PubMed PMID: 24004891.
- 1266 53. Killilea DW, Schultz K. Pre-analytical variables influence zinc measurement in blood
1267 samples. *PLOS ONE*. 2023.
- 1268 54. Pfeiffer CM, Zhang M, Lacher DA, Molloy AM, Tamura T, Yetley EA, et al. Comparison
1269 of serum and red blood cell folate microbiologic assays for national population surveys. *J Nutr*.
1270 2011;141(7):1402-9. Epub 2011/05/27. doi: 10.3945/jn.111.141515. PubMed PMID: 21613453;
1271 PubMed Central PMCID: PMC3113292.
- 1272 55. Tanumihardjo SA, Russell RM, Stephensen CB, Gannon BM, Craft NE, Haskell MJ, et al.
1273 Biomarkers of Nutrition for Development (BOND)-Vitamin A Review. *J Nutr*.
1274 2016;146(9):1816s-48s. Epub 2016/08/12. doi: 10.3945/jn.115.229708. PubMed PMID:
1275 27511929; PubMed Central PMCID: PMC4997277.
- 1276 56. Williams RL. A note on robust variance estimation for cluster-correlated data. *Biometrics*.
1277 2000;56:645-6.
- 1278 57. Bland JM, Altman DG. Best (but oft forgotten) practices: testing for treatment effects in
1279 randomized trials by separate analyses of changes from baseline in each group is a misleading
1280 approach. *The American journal of clinical nutrition*. 2015;102(5):991-4. Epub 2015/09/12. doi:
1281 10.3945/ajcn.115.119768. PubMed PMID: 26354536.

- 1282 58. O'Connor C, Joffe H. Intercoder reliability in qualitative research: Debates and practical
1283 guidelines. *International Journal of Qualitative Methods*. 2020. doi: 10.1177/1609406919899220.
- 1284 59. International Committee of Medical Journal Editors. Recommendations for the Conduct,
1285 Reporting, Editing, and Publication of Scholarly Work in Medical Journals 2022 [cited 2022 May
1286 16]. Available from: <https://www.icmje.org/icmje-recommendations.pdf>.
- 1287 60. Engle-Stone R, Vosti SA, Luo H, Kagin J, Tarini A, Adams KP, et al. Weighing the risks
1288 of high intakes of selected micronutrients compared with the risks of deficiencies. *Ann N Y Acad
1289 Sci*. 2019;1446(81-101).

1290

1291

1292

1293

Online Supporting Material: Effect of household use of multiple micronutrient-fortified bouillon on micronutrient status among women and children in two districts in the Northern Region of Ghana: Protocol for the Condiment Micronutrient Innovation Trial (CoMIT), a community-based randomized controlled trial.

S1. Table of primary outcomes

Physiological group	Primary outcomes
Non-pregnant, non-lactating women of reproductive age (WRA)	<ul style="list-style-type: none"> • Change in micronutrient status after 38 weeks: <ul style="list-style-type: none"> ○ Total body vitamin A stores and liver vitamin A concentration (measured by retinol isotope dilution) ○ Plasma ferritin and soluble transferrin receptor (sTfR) concentrations, and calculated body iron stores (BIS) ○ Plasma zinc concentration ○ Erythrocyte folate concentrations ○ Plasma vitamin B12 concentration • Change in hemoglobin (Hb) concentration after 38 weeks
Children 2-5 y	<ul style="list-style-type: none"> • Change in micronutrient status after 38 weeks: <ul style="list-style-type: none"> ○ Plasma retinol binding protein (RBP) concentrations ○ Plasma ferritin and soluble transferrin receptor (sTfR) concentrations, and calculated body iron stores (BIS) ○ Plasma zinc concentration ○ Plasma folate concentration ○ Plasma vitamin B12 concentration • Change in hemoglobin concentration after 38 weeks
Non-pregnant, lactating women	<ul style="list-style-type: none"> • Change in breast milk vitamin A concentration after 12 weeks (controlling for milk fat content) • Change in breast milk vitamin B12 concentration after 12 weeks

Online Supporting Material: Effect of household use of multiple micronutrient-fortified bouillon on micronutrient status among women and children in two districts in the Northern Region of Ghana: Protocol for the Condiment Micronutrient Innovation Trial (CoMIT), a community-based randomized controlled trial.

S2. Table of secondary outcomes

Target group	Secondary outcomes
Household	<ul style="list-style-type: none"> Household consumption of bouillon (total and per capita) Adherence (consumption of study-provided bouillon, expressed as % of total household bouillon consumption)
Non-pregnant, non-lactating women of reproductive age	<ul style="list-style-type: none"> Change in serum or plasma retinol and retinol binding protein (RBP) concentrations after 38 weeks Change in serum folate concentrations after 38 weeks Change in urinary iodine concentrations after 38 weeks Urinary sodium concentrations, and sodium:potassium ratio Change in prevalence of micronutrient deficiency after 38 weeks Change in prevalence of anaemia after 38 weeks Inflammation (concentrations of C-reactive protein (CRP) and alpha-1-acid glycoprotein (AGP) and prevalence of elevated values, and other markers including amyloid A, monocyte chemoattractant protein-1 (MCP-1), IL-6, IL-10, IL1beta, and adiponectin at baseline and endline) Current or recent malaria (by rapid diagnostic test; RDT) at baseline and endline Morbidity (cumulative days of symptoms over study duration) Dietary intake of bouillon, salt, fortifiable foods, energy, macronutrients, and micronutrients Blood pressure and hypertension prevalence
Children 2-5 y	<ul style="list-style-type: none"> Change in urinary iodine concentrations after 38 weeks Change in prevalence of micronutrient deficiency after 38 weeks Change in prevalence of anaemia after 38 weeks Change in plasma retinol concentrations after 38 weeks Inflammation (concentrations of C-reactive protein (CRP) and alpha-1-acid glycoprotein (AGP) and prevalence of elevated values) at baseline and endline Current or recent malaria (by RDT) at baseline and endline Faecal calprotectin concentrations at baseline and endline Faecal microbiota at baseline and endline Morbidity (cumulative days of symptoms over study duration) Dietary intake of bouillon, salt, fortifiable foods, energy, macronutrients, and micronutrients Anthropometric measurements (change in height-for-age and weight-for-height Z-scores; prevalence of stunting and wasting) Change in Malawi Development Assessment Tool (MDAT) scores in 4 domains (gross motor, fine motor, language, social) after 38 weeks Change in Early Years Toolbox (EYT) scores after 38 weeks
Non-pregnant, lactating women	<ul style="list-style-type: none"> Change in prevalence of low milk nutrient concentrations after 12 weeks Dietary intake of bouillon, salt, fortifiable foods, energy, macronutrients, and micronutrients Morbidity (cumulative days of symptoms over study duration)

S3. Table of specification and definitions of hemoglobin and micronutrient biomarker variables for children 2-5 years of age¹

Outcome variables	Definitions of dichotomous outcome variables
Hemoglobin (Hb; g/L)	
Anemia	Hb < 110 g/L (WHO, 2011)
Mild anemia	Hb 100-109 g/L
Moderate to severe anemia	Hb 70-99 g/L
Severe anemia	Hb < 70 g/L
Plasma ferritin (µg/L)	
Iron deficiency (low plasma ferritin concentration)	Plasma ferritin < 12 µg/L (WHO, 2011)
Plasma soluble transferrin receptor concentration (sTfR; mg/L)	
Elevated plasma sTfR concentration	Plasma sTfR > 8.3 mg/L (Erhardt, Estes, Pfeiffer, Biesalski, & Craft, 2004)
Any iron deficiency	Plasma ferritin < 12 µg/L and/or sTfR > 8.3 mg/L
Iron deficiency anemia	(plasma ferritin < 12 µg/L and/or sTfR > 8.3 mg/L) and Hb < 110 g/L (World Health Organization)
Low ferritin and anemia	Plasma ferritin < 12 µg/L and Hb < 110 g/L (World Health Organization)
Body iron stores (BIS; mg/kg)	
Low BIS	< 0 mg/kg (Cook, Flowers, & Skikne, 2003)
Plasma zinc concentration (µg/dL)	
Low plasma zinc concentration	Plasma zinc < 65 µg/dL (Brown et al., 2004)
Plasma retinol concentration (µmol/L)	
Low retinol	Plasma retinol < 0.70 µmol/L (WHO, 2011)
Marginal retinol	Plasma retinol < 1.05 µmol/L
Plasma retinol binding protein concentration (RBP; µmol/L) ²	
Low RBP	Study-specific cut-off to be determined
Marginal RBP	Study-specific cut-off to be determined
Plasma folate concentrations (nmol/L)	
Low folate	< 10 nmol/L (L. B. Bailey et al., 2015)
Low folate and anemia	Plasma folate < 10nmol/L and anemia (Hb < 120 g/L)
Plasma vitamin B12 concentrations (pmol/L)	
Low vitamin B12	< 148 pmol/L (Allen et al., 2018)
Depleted vitamin B12	< 221 pmol/L
Low B12 and anemia	Vitamin B12 < 148 pmol/L and anemia (Hb < 120 g/L)

¹Hb, hemoglobin; BIS, body iron stores; RBP, retinol binding protein; sTfR, soluble transferrin receptor. Procedures for adjusting micronutrient biomarkers for inflammation and methodological factors, as appropriate, will be described in the Statistical Analysis Plan. ²There is currently no internationally established cut-off for RBP that reflects a plasma retinol concentration of < 0.70 µmol/L or < 1.05 µmol/L, and it has been recommended that trials determine the relationship between retinol and RBP in a sub-sample of the trial population to establish study-specific RBP cut-offs.

S4. Table of specification and definitions of hemoglobin and micronutrient biomarkers variables for non-pregnant, non-lactating women of reproductive age¹

Outcome variables	Definitions of dichotomous outcome variables
Hemoglobin (Hb; g/L)	
Anemia	Hb < 120 g/L (WHO, 2011)
Mild anemia	Hb 110-119 g/L
Moderate to severe anemia	Hb 80-109 g/L
Severe anemia	Hb < 80 g/L
Hematocrit (Hct; L/L)	
Anemia	Hct < 0.36 L/L (World Health Organization)
Plasma ferritin (µg/L)	
Iron deficiency (low plasma ferritin concentration)	Plasma ferritin < 15 µg/L (WHO, 2011)
Plasma soluble transferrin receptor concentration (sTfR; mg/L)	
Elevated plasma sTfR concentration	Plasma sTfR > 8.3 mg/L (Erhardt et al., 2004)
Any iron deficiency	Plasma ferritin < 15 µg/L and/or sTfR > 8.3 mg/L
Iron deficiency anemia	(Plasma ferritin < 15 µg/L and/or sTfR > 8.3 mg/L) and (Hb < 120 g/L or Hct < 0.36 L/L)
Low ferritin and anemia	Plasma ferritin < 15 µg/L and (Hb < 120 g/L or Hct < 0.36 L/L)
Body iron stores (BIS; mg/kg)	
Low BIS	BIS < 0 mg/kg (Cook et al., 2003)
Plasma zinc concentration (µg/dL)	
Low plasma zinc concentration	Plasma zinc < 70 µg/dL (fasting); < 66 µg/dL (non-fasting) (Brown et al., 2004)
Liver vitamin A concentrations	
Low liver vitamin A concentrations	< 0.07 µmol/g liver and < 0.1 µmol/g liver
Serum (plasma) retinol concentration (µmol/L)	
Low retinol	Serum (plasma) retinol < 0.70 µmol/L (WHO, 2011)
Marginal retinol	Serum (plasma) retinol < 1.05 µmol/L
Plasma retinol binding protein concentration (RBP; µmol/L) ²	
Low RBP	Study-specific cut-off to be determined
Marginal RBP	Study-specific cut-off to be determined
Serum folate concentrations (nmol/L)	
Low serum folate	< 10 nmol/L (L. B. Bailey et al., 2015)
Erythrocyte (RBC) folate concentrations	
Low RBC folate	< 340 nmol/L (L. B. Bailey et al., 2015)
Low folate and anemia	RBC folate < 340 nmol/L or serum folate < 10nmol/L and anemia (Hb < 120 g/L)
Plasma vitamin B12 concentrations (pmol/L)	
Low vitamin B12	< 148 pmol/L (Allen et al., 2018)
Depleted vitamin B12	< 221 pmol/L
Low B12 and anemia	Vitamin B12 < 148 pmol/L and anemia (Hb < 120 g/L)

Online Supporting Material: Effect of household use of multiple micronutrient-fortified bouillon on micronutrient status among women and children in two districts in the Northern Region of Ghana: Protocol for the Condiment Micronutrient Innovation Trial (CoMIT), a community-based randomized controlled trial.

¹Hb, hemoglobin; Hct, haematocrit; BIS, body iron stores; RBC, red blood cell; RBP, retinol binding protein; sTfR, soluble transferrin receptor. Procedures for adjusting micronutrient biomarkers for inflammation and methodological factors, as appropriate, will be described in the Statistical Analysis Plan. ²There is currently no internationally established cut-off for RBP that reflects a plasma retinol concentration of $< 0.70 \mu\text{mol/L}$ or $< 1.05 \mu\text{mol/L}$, and it has been recommended that trials determine the relationship between retinol and RBP in a sub-sample of the trial population to establish study-specific RBP cut-offs.

S5. Supplemental Methods: Inclusion, Exclusion, and Deferral Criteria

Inclusion/exclusion criteria at recruitment (home visit):

Household

Inclusion criteria are:

- (i) Head of household provides oral consent for the participation of household members (index participants), and willingness to have study-provided bouillon cubes used in their household cooking for the next 10 months;

Exclusion criteria are:

- (i) Reported chronic medical condition requiring frequent blood transfusion (e.g. severe forms of thalassemia) among any household members;
- (ii) Current participation of any household member in a clinical trial;
- (iii) Reported shrimp, wheat, milk, soy, eggs, celery, fish, or mollusk allergy, or a previous adverse reaction to bouillon by the participant or any member of their household.

Non-pregnant, non-lactating women of reproductive age (WRA)

Inclusion criteria are:

- (i) Non-pregnant non-lactating women of reproductive age (15 - 49 years);
- (ii) Signed the informed consent form (or in the case of adolescents 15-17 years of age, unmarried and still living with their parents, assent provided from the index participant and consent from a parent or guardian);
- (iii) Planning to remain in the study area for the next 10 months;
- (iv) Willing to use study-provided bouillon in household cooking for the next 10 months;
- (v) Not planning to become pregnant during the next 10 months.

Potential participants will be excluded if any of the following apply:

- (i) Severe illness warranting immediate hospital referral;
- (ii) COVID-19 diagnosis or exposure¹ in the previous two weeks [*individual may repeat eligibility assessment once after a deferral period of at least 2 weeks*];
- (iii) Presence of morbidity symptoms suggesting COVID-19 infection (fever [temperature $\geq 38^{\circ}\text{C}$], chills/shaking, dry cough, shortness of breath or difficulty breathing, loss of smell or taste within the past 72 hours) [*individual*

¹ Exposure based on the WHO definition: “A contact is defined as anyone who had direct contact or was within 1 metre for at least 15 minutes with a person infected with the virus that causes COVID-19.” <https://www.who.int/news-room/q-a-detail/coronavirus-disease-covid-19-contact-tracing>. Diagnosis may be based on positive test or diagnosis by a medical professional based on clinical symptoms.

- may repeat eligibility assessment once after a deferral period of at least 2 weeks];*
- (iv) Chronic severe medical condition (e.g. malignancy) or congenital anomalies requiring frequent medical attention or potentially interfering with nutritional status;
 - (v) Unable to provide informed consent due to impaired decision-making abilities.

Children 2-5 years of age (24-59 mo)

Inclusion criteria are:

- (i) Child 2-5 years of age (24-59 mo);
- (ii) Signed informed consent for the child's participation from a parent or guardian;
- (iii) Planning to remain in the study area for the next 10 months;
- (iv) Caregiver willing to use study-provided bouillon in household cooking for the next 10 months.

Potential participants will be excluded if any of the following apply:

- (i) Severe illness warranting immediate hospital referral;
- (ii) COVID-19 diagnosis or exposure in the previous two weeks [*individual may repeat eligibility assessment once after a deferral period of at least 2 weeks];*
- (iii) Presence of morbidity symptoms suggesting COVID-19 infection (fever, [temperature $\geq 38^{\circ}\text{C}$], chills/shaking, dry cough, shortness of breath or difficulty breathing, loss of smell or taste within the past 72 hours) [*individual may repeat eligibility assessment once after a deferral period of at least 2 weeks];*
- (iv) Mid-upper arm circumference (MUAC) < 11.5 cm;
- (v) Chronic severe medical condition (e.g. malignancy) or congenital anomalies requiring frequent medical attention or potentially interfering with nutritional status.

Lactating women

Inclusion criteria are:

- (i) Non-pregnant women of reproductive age (15 - 49 years); currently breastfeeding a child who is 4-18 months of age;
- (ii) Signed the informed consent form (or in the case of adolescents 15-17 years of age, unmarried and still living with their parents, provide assent from the index participant and consent from a parent or guardian);
- (iii) Planning to remain in the study area for the next 4 months;
- (iv) Planning to breastfeed for the next 4 months;
- (v) Willing to use study-provided bouillon in household cooking for the next 4 months;
- (vi) Not planning to become pregnant during the next 4 months.

Potential participants will be excluded if any of the following apply:

- (i) Pregnancy (determined by self-report);
- (ii) Severe illness warranting immediate hospital referral;
- (iii) COVID-19 diagnosis or exposure in the previous two weeks [*individual may repeat eligibility assessment once after a deferral period of at least 2 weeks*];
- (iv) Presence of morbidity symptoms suggesting COVID-19 infection (fever [temperature $\geq 38^{\circ}\text{C}$], chills/shaking, dry cough, shortness of breath or difficulty breathing, loss of smell or taste within the past 72 hours) [*individual may repeat eligibility assessment once after a deferral period of at least 2 weeks*];
- (v) Chronic severe medical condition (e.g. malignancy) or congenital anomalies requiring frequent medical attention or potentially interfering with nutritional status;
- (vi) Unable to provide informed consent due to impaired decision-making abilities.

Exclusion criteria at baseline screening visit (WRA only):

Non-pregnant, non-lactating women of reproductive age

Potential participants will be excluded if any of the following apply:

- (i) Hemoglobin < 80 g/L **at baseline screening visit**;
- (ii) Severe illness warranting immediate hospital referral;
- (iii) COVID-19 diagnosis or exposure in the previous two weeks [*individual may repeat eligibility assessment once after a deferral period of at least 2 weeks*];
- (iv) Presence of morbidity symptoms suggesting COVID-19 infection (fever [temperature $\geq 38^{\circ}\text{C}$], chills/shaking, dry cough, shortness of breath or difficulty breathing, loss of smell or taste within the past 72 hours) [*individual may repeat eligibility assessment once after a deferral period of at least 2 weeks*];
- (v) Recent diarrhea [≥ 3 liquid or semiliquid stools in 72 hours]) [*individual may repeat eligibility assessment once after a deferral period of at least 2 weeks*];
- (vi) Reported consumption of vitamin A-rich foods (e.g., liver) in the previous 24 hours [*individual may repeat eligibility assessment once after a deferral period of at least 2 weeks*];
- (vii) Pregnancy (as ascertained via urine pregnancy test for human chorionic gonadotropin, HCG, on the day of isotope dosing);
- (viii) Incomplete consumption of vitamin A isotope dose;
- (ix) Positive malaria RDT on the day of isotope dosing [*individual may repeat eligibility assessment once after a deferral period of at least 2 weeks*];
- (x) CRP > 5 mg/L on the day of isotope dosing [*individual may repeat eligibility assessment once after a deferral period of at least 2 weeks*].

Exclusion criteria at baseline visit:

Non-pregnant, non-lactating women of reproductive age

- (i) Hemoglobin < 80 g/L;
- (ii) Severe illness warranting immediate hospital referral;
- (iii) COVID-19 diagnosis or exposure in the previous two weeks [*individual may repeat eligibility assessment once after a deferral period of at least 2 weeks*];
- (iv) Presence of morbidity symptoms suggesting COVID-19 infection (fever [temperature $\geq 38^{\circ}\text{C}$], chills/shaking, dry cough, shortness of breath or difficulty breathing, loss of smell or taste within the past 72 hours) [*individual may repeat eligibility assessment once after a deferral period of at least 2 weeks*];
- (v) Pregnancy (determined by self-report).

Children 2-5 years of age

- (i) Hemoglobin < 70 g/L;
- (ii) Severe illness warranting immediate hospital referral;
- (iii) COVID-19 diagnosis or exposure in the previous two weeks [*individual may repeat eligibility assessment once after a deferral period of at least 2 weeks*];
- (iv) Presence of morbidity symptoms suggesting COVID-19 infection (fever [temperature $\geq 38^{\circ}\text{C}$], chills/shaking, dry cough, shortness of breath or difficulty breathing, loss of smell or taste within the past 72 hours) [*individual may repeat eligibility assessment once after a deferral period of at least 2 weeks*];
- (v) Severe acute malnutrition at baseline (weight-for-height Z-score < -3 SD or bilateral oedema).

Lactating women

- (i) Severe illness warranting immediate hospital referral;
- (xi) COVID-19 diagnosis or exposure in the previous two weeks [*individual may repeat eligibility assessment once after a deferral period of at least 2 weeks*];
- (xii) Presence of morbidity symptoms suggesting COVID-19 infection (fever [temperature $\geq 38^{\circ}\text{C}$], chills/shaking, dry cough, shortness of breath or difficulty breathing, or loss of taste or smell within the past 72 hours) [*individual may repeat eligibility assessment once after a deferral period of at least 2 weeks*];
- (ii) Pregnancy (determined by self-report);
- (iii) Cessation of lactation, or planning to discontinue breastfeeding in the next three months.

Exclusion criteria during course of the intervention:

Non-pregnant, non-lactating women of reproductive age

- (i) Pregnancy (determined by self-report);
- (ii) Pregnancy (as ascertained via urine pregnancy test for human chorionic gonadotropin at the endline 1 visit [pre-endline isotope dosing]).

Lactating women

- (i) Cessation of lactation (determined by self-report);
- (ii) Pregnancy (determined by self-report).

Note: If a COVID-19 exposure or diagnosis, or if COVID-19-related morbidity symptoms are reported during biweekly visits during the intervention trial, the participant will be allowed to remain enrolled, but field staff will follow procedures for “no contact” study activities (e.g., “no contact” bouillon ration drop-off) for a 2-week period.

Deferral criteria for endline assessments

Replicate endline assessments (3 weeks apart for blood biomarkers and 1 week apart for breast milk biomarkers) will be conducted for each of the primary outcomes except estimation of total body vitamin A stores among women. For all participants, each endline assessment will be deferred if any of the following apply:

- (i) COVID-19 exposure or positive test in the previous two weeks [*individual may repeat eligibility assessment once after a deferral period of at least 3 weeks for WRA and children or at least 2 weeks for lactating women*];
- (ii) Presence of morbidity symptoms suggesting COVID-19 infection (fever [temperature $\geq 38^{\circ}\text{C}$], chills/shaking, dry cough, shortness of breath or difficulty breathing, or loss of taste or smell within the past 72 hours) [*individual may repeat eligibility assessment once after a deferral period of at least 3 weeks for WRA and children or at least 2 weeks for lactating women*].

For a participant who has both endline visits deferred, the maximum duration of participation in the study would be 44 weeks (that is, if Endline 1 is deferred from 35 weeks to 38 weeks and Endline 2 is deferred from 41 weeks to 44 weeks). In this case the household would continue to receive their usual supply of study bouillon cubes until the participants complete the Endline 2 visit. Based on pilot data we expect this situation to be rare.

Note: If a non-pregnant, non-lactating WRA has a hemoglobin concentration < 80 g/L, or a 2-5 year old child has a hemoglobin concentration < 70 g/L or a WHZ < -3 SD at the first endline

visit, participants may remain in the trial, but will not participate in the second endline blood sample.

Additional exclusion criteria for pre-endline isotope dose (WRA only):

Non-pregnant, non-lactating women of reproductive age

The pre-endline vitamin A isotope dose will be administered after the endline 1 blood sample. The isotope dose will not be given if any of the following apply:

- (i) Hemoglobin < 80 g/L

Additional deferral criteria for pre-endline isotope dose (WRA only):

Non-pregnant, non-lactating women of reproductive age

The pre-endline vitamin A isotope dose will be administered after the endline 1 blood sample. The isotope dose will be deferred if any of the following apply:

- (i) Recent diarrhea [≥ 3 liquid or semiliquid stools in 72 hours] *[individual may repeat eligibility assessment once after a deferral period of at least 3 weeks];*
- (ii) Reported consumption of vitamin A-rich foods (e.g., liver) in the previous 24 hours *[individual may repeat eligibility assessment up once after a deferral period of at least 3 weeks];*
- (iii) Positive malaria RDT on the day of isotope dosing *[individual may repeat eligibility assessment once after a deferral period of at least 3 weeks];*
- (iv) CRP > 5 mg/L on the day of isotope dosing *[individual may repeat eligibility assessment once after a deferral period of at least 3 weeks].*